#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Neurofeedback training for alcohol dependence versus treatment as usual: study protocol for a randomized controlled trial Background Real-time functional magnetic resonance imaging (rtfMRI) is used for neurofeedback training (NFT).
1-1	0-13	Neurofeedback	_
1-2	14-22	training	_
1-3	23-26	for	_
1-4	27-34	alcohol	_
1-5	35-45	dependence	_
1-6	46-52	versus	_
1-7	53-62	treatment	_
1-8	63-65	as	_
1-9	66-71	usual	_
1-10	72-73	:	_
1-11	74-79	study	_
1-12	80-88	protocol	_
1-13	89-92	for	_
1-14	93-94	a	_
1-15	95-105	randomized	_
1-16	106-116	controlled	_
1-17	117-122	trial	_
1-18	123-133	Background	_
1-19	134-143	Real-time	_
1-20	144-154	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-21	155-163	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-22	164-173	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-23	174-181	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-24	182-183	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-25	184-190	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-26	191-192	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-27	193-195	is	_
1-28	196-200	used	_
1-29	201-204	for	_
1-30	205-218	neurofeedback	_
1-31	219-227	training	_
1-32	228-229	(	_
1-33	230-233	NFT	_
1-34	234-235	)	_
1-35	236-237	.	_

Text=Preliminary results suggest that it can help patients to control their symptoms.
2-1	238-249	Preliminary	_
2-2	250-257	results	_
2-3	258-265	suggest	_
2-4	266-270	that	_
2-5	271-273	it	_
2-6	274-277	can	_
2-7	278-282	help	_
2-8	283-291	patients	_
2-9	292-294	to	_
2-10	295-302	control	_
2-11	303-308	their	_
2-12	309-317	symptoms	_
2-13	318-319	.	_

Text=This study uses rtfMRI NFT for relapse prevention in alcohol dependence.
3-1	320-324	This	_
3-2	325-330	study	_
3-3	331-335	uses	_
3-4	336-342	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
3-5	343-346	NFT	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
3-6	347-350	for	_
3-7	351-358	relapse	_
3-8	359-369	prevention	_
3-9	370-372	in	_
3-10	373-380	alcohol	_
3-11	381-391	dependence	_
3-12	392-393	.	_

Text=Methods/design Participants are alcohol-dependent patients who have completed a detoxification programme within the past 6 months and have remained abstinent.
4-1	394-408	Methods/design	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
4-2	409-421	Participants	_
4-3	422-425	are	_
4-4	426-443	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-5	444-452	patients	_
4-6	453-456	who	_
4-7	457-461	have	_
4-8	462-471	completed	_
4-9	472-473	a	_
4-10	474-488	detoxification	_
4-11	489-498	programme	_
4-12	499-505	within	_
4-13	506-509	the	_
4-14	510-514	past	_
4-15	515-516	6	_
4-16	517-523	months	_
4-17	524-527	and	_
4-18	528-532	have	_
4-19	533-541	remained	_
4-20	542-551	abstinent	_
4-21	552-553	.	_

Text=Potential participants are screened for eligibility, and those who are eligible are randomly assigned to the treatment group (receiving rtfMRI NFT in addition to treatment as usual) or the control group (receiving only treatment as usual).
5-1	554-563	Potential	_
5-2	564-576	participants	_
5-3	577-580	are	_
5-4	581-589	screened	_
5-5	590-593	for	_
5-6	594-605	eligibility	_
5-7	606-607	,	_
5-8	608-611	and	_
5-9	612-617	those	_
5-10	618-621	who	_
5-11	622-625	are	_
5-12	626-634	eligible	_
5-13	635-638	are	_
5-14	639-647	randomly	_
5-15	648-656	assigned	_
5-16	657-659	to	_
5-17	660-663	the	_
5-18	664-673	treatment	_
5-19	674-679	group	_
5-20	680-681	(	_
5-21	682-691	receiving	_
5-22	692-698	rtfMRI	_
5-23	699-702	NFT	_
5-24	703-705	in	_
5-25	706-714	addition	_
5-26	715-717	to	_
5-27	718-727	treatment	_
5-28	728-730	as	_
5-29	731-736	usual	_
5-30	737-738	)	_
5-31	739-741	or	_
5-32	742-745	the	_
5-33	746-753	control	_
5-34	754-759	group	_
5-35	760-761	(	_
5-36	762-771	receiving	_
5-37	772-776	only	_
5-38	777-786	treatment	_
5-39	787-789	as	_
5-40	790-795	usual	_
5-41	796-797	)	_
5-42	798-799	.	_

Text=Participants in both groups are administered baseline assessments to measure their alcohol consumption and severity of dependence and a variety of psychological and behavioural characteristics that are hypothesised to predict success with rtfMRI NFT.
6-1	800-812	Participants	_
6-2	813-815	in	_
6-3	816-820	both	_
6-4	821-827	groups	_
6-5	828-831	are	_
6-6	832-844	administered	_
6-7	845-853	baseline	_
6-8	854-865	assessments	_
6-9	866-868	to	_
6-10	869-876	measure	_
6-11	877-882	their	_
6-12	883-890	alcohol	_
6-13	891-902	consumption	_
6-14	903-906	and	_
6-15	907-915	severity	_
6-16	916-918	of	_
6-17	919-929	dependence	_
6-18	930-933	and	_
6-19	934-935	a	_
6-20	936-943	variety	_
6-21	944-946	of	_
6-22	947-960	psychological	_
6-23	961-964	and	_
6-24	965-976	behavioural	_
6-25	977-992	characteristics	_
6-26	993-997	that	_
6-27	998-1001	are	_
6-28	1002-1014	hypothesised	_
6-29	1015-1017	to	_
6-30	1018-1025	predict	_
6-31	1026-1033	success	_
6-32	1034-1038	with	_
6-33	1039-1045	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
6-34	1046-1049	NFT	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingDay
6-35	1050-1051	.	_

Text=During the following 4 months, experimental participants are given six NFT sessions, and before and after each session various alcohol-related measures are taken.
7-1	1052-1058	During	_
7-2	1059-1062	the	_
7-3	1063-1072	following	_
7-4	1073-1074	4	_
7-5	1075-1081	months	_
7-6	1082-1083	,	_
7-7	1084-1096	experimental	_
7-8	1097-1109	participants	_
7-9	1110-1113	are	_
7-10	1114-1119	given	_
7-11	1120-1123	six	_
7-12	1124-1127	NFT	_
7-13	1128-1136	sessions	_
7-14	1137-1138	,	_
7-15	1139-1142	and	_
7-16	1143-1149	before	_
7-17	1150-1153	and	_
7-18	1154-1159	after	_
7-19	1160-1164	each	_
7-20	1165-1172	session	_
7-21	1173-1180	various	_
7-22	1181-1196	alcohol-related	_
7-23	1197-1205	measures	_
7-24	1206-1209	are	_
7-25	1210-1215	taken	_
7-26	1216-1217	.	_

Text=Participants in the control group are given the same measures to coincide with their timing in the experimental group.
8-1	1218-1230	Participants	_
8-2	1231-1233	in	_
8-3	1234-1237	the	_
8-4	1238-1245	control	_
8-5	1246-1251	group	_
8-6	1252-1255	are	_
8-7	1256-1261	given	_
8-8	1262-1265	the	_
8-9	1266-1270	same	_
8-10	1271-1279	measures	_
8-11	1280-1282	to	_
8-12	1283-1291	coincide	_
8-13	1292-1296	with	_
8-14	1297-1302	their	_
8-15	1303-1309	timing	_
8-16	1310-1312	in	_
8-17	1313-1316	the	_
8-18	1317-1329	experimental	_
8-19	1330-1335	group	_
8-20	1336-1337	.	_

Text=Eight and 12 months after the baseline assessment, both groups are followed up with a battery of measures.
9-1	1338-1343	Eight	_
9-2	1344-1347	and	_
9-3	1348-1350	12	_
9-4	1351-1357	months	_
9-5	1358-1363	after	_
9-6	1364-1367	the	_
9-7	1368-1376	baseline	_
9-8	1377-1387	assessment	_
9-9	1388-1389	,	_
9-10	1390-1394	both	_
9-11	1395-1401	groups	_
9-12	1402-1405	are	_
9-13	1406-1414	followed	_
9-14	1415-1417	up	_
9-15	1418-1422	with	_
9-16	1423-1424	a	_
9-17	1425-1432	battery	_
9-18	1433-1435	of	_
9-19	1436-1444	measures	_
9-20	1445-1446	.	_

Text=The primary research questions are whether NFT can be used to teach participants to down-regulate their brain activation in the presence of alcohol stimuli or to up-regulate their brain activation in response to pictures related to healthy goal pursuits, and, if so, whether this translates into reductions in alcohol consumption.
10-1	1447-1450	The	_
10-2	1451-1458	primary	_
10-3	1459-1467	research	_
10-4	1468-1477	questions	_
10-5	1478-1481	are	_
10-6	1482-1489	whether	_
10-7	1490-1493	NFT	_
10-8	1494-1497	can	_
10-9	1498-1500	be	_
10-10	1501-1505	used	_
10-11	1506-1508	to	_
10-12	1509-1514	teach	_
10-13	1515-1527	participants	_
10-14	1528-1530	to	_
10-15	1531-1544	down-regulate	_
10-16	1545-1550	their	_
10-17	1551-1556	brain	_
10-18	1557-1567	activation	_
10-19	1568-1570	in	_
10-20	1571-1574	the	_
10-21	1575-1583	presence	_
10-22	1584-1586	of	_
10-23	1587-1594	alcohol	_
10-24	1595-1602	stimuli	_
10-25	1603-1605	or	_
10-26	1606-1608	to	_
10-27	1609-1620	up-regulate	_
10-28	1621-1626	their	_
10-29	1627-1632	brain	_
10-30	1633-1643	activation	_
10-31	1644-1646	in	_
10-32	1647-1655	response	_
10-33	1656-1658	to	_
10-34	1659-1667	pictures	_
10-35	1668-1675	related	_
10-36	1676-1678	to	_
10-37	1679-1686	healthy	_
10-38	1687-1691	goal	_
10-39	1692-1700	pursuits	_
10-40	1701-1702	,	_
10-41	1703-1706	and	_
10-42	1707-1708	,	_
10-43	1709-1711	if	_
10-44	1712-1714	so	_
10-45	1715-1716	,	_
10-46	1717-1724	whether	_
10-47	1725-1729	this	_
10-48	1730-1740	translates	_
10-49	1741-1745	into	_
10-50	1746-1756	reductions	_
10-51	1757-1759	in	_
10-52	1760-1767	alcohol	_
10-53	1768-1779	consumption	_
10-54	1780-1781	.	_

Text=The primary outcome measures will be those derived from the functional brain imaging data.
11-1	1782-1785	The	_
11-2	1786-1793	primary	_
11-3	1794-1801	outcome	_
11-4	1802-1810	measures	_
11-5	1811-1815	will	_
11-6	1816-1818	be	_
11-7	1819-1824	those	_
11-8	1825-1832	derived	_
11-9	1833-1837	from	_
11-10	1838-1841	the	_
11-11	1842-1852	functional	_
11-12	1853-1858	brain	_
11-13	1859-1866	imaging	_
11-14	1867-1871	data	_
11-15	1872-1873	.	_

Text=We are interested in improvements (i.e., reductions) in participants ’ alcohol consumption from pretreatment levels, as indicated by three continuous variables, not simply whether or not the person has remained abstinent.
12-1	1874-1876	We	_
12-2	1877-1880	are	_
12-3	1881-1891	interested	_
12-4	1892-1894	in	_
12-5	1895-1907	improvements	_
12-6	1908-1909	(	_
12-7	1910-1914	i.e.	_
12-8	1915-1916	,	_
12-9	1917-1927	reductions	_
12-10	1928-1929	)	_
12-11	1930-1932	in	_
12-12	1933-1945	participants	_
12-13	1946-1947	’	_
12-14	1948-1955	alcohol	_
12-15	1956-1967	consumption	_
12-16	1968-1972	from	_
12-17	1973-1985	pretreatment	_
12-18	1986-1992	levels	_
12-19	1993-1994	,	_
12-20	1995-1997	as	_
12-21	1998-2007	indicated	_
12-22	2008-2010	by	_
12-23	2011-2016	three	_
12-24	2017-2027	continuous	_
12-25	2028-2037	variables	_
12-26	2038-2039	,	_
12-27	2040-2043	not	_
12-28	2044-2050	simply	_
12-29	2051-2058	whether	_
12-30	2059-2061	or	_
12-31	2062-2065	not	_
12-32	2066-2069	the	_
12-33	2070-2076	person	_
12-34	2077-2080	has	_
12-35	2081-2089	remained	_
12-36	2090-2099	abstinent	_
12-37	2100-2101	.	_

Text=The indices of interest are percentage of days abstinent, drinks per drinking day, and percentage of days of heavy drinking.
13-1	2102-2105	The	_
13-2	2106-2113	indices	_
13-3	2114-2116	of	_
13-4	2117-2125	interest	_
13-5	2126-2129	are	_
13-6	2130-2140	percentage	_
13-7	2141-2143	of	_
13-8	2144-2148	days	_
13-9	2149-2158	abstinent	_
13-10	2159-2160	,	_
13-11	2161-2167	drinks	_
13-12	2168-2171	per	_
13-13	2172-2180	drinking	_
13-14	2181-2184	day	_
13-15	2185-2186	,	_
13-16	2187-2190	and	_
13-17	2191-2201	percentage	_
13-18	2202-2204	of	_
13-19	2205-2209	days	_
13-20	2210-2212	of	_
13-21	2213-2218	heavy	_
13-22	2219-2227	drinking	_
13-23	2228-2229	.	_

Text=General linear models will be used to compare the NFT group and the control group on these measures.
14-1	2230-2237	General	_
14-2	2238-2244	linear	_
14-3	2245-2251	models	_
14-4	2252-2256	will	_
14-5	2257-2259	be	_
14-6	2260-2264	used	_
14-7	2265-2267	to	_
14-8	2268-2275	compare	_
14-9	2276-2279	the	_
14-10	2280-2283	NFT	_
14-11	2284-2289	group	_
14-12	2290-2293	and	_
14-13	2294-2297	the	_
14-14	2298-2305	control	_
14-15	2306-2311	group	_
14-16	2312-2314	on	_
14-17	2315-2320	these	_
14-18	2321-2329	measures	_
14-19	2330-2331	.	_

Text=Discussion Relapse in alcohol dependence is a recurring problem, and the present evaluation of the role of rtfMRI in its treatment holds promise for identifying a way to prevent relapse.
15-1	2332-2342	Discussion	_
15-2	2343-2350	Relapse	_
15-3	2351-2353	in	_
15-4	2354-2361	alcohol	_
15-5	2362-2372	dependence	_
15-6	2373-2375	is	_
15-7	2376-2377	a	_
15-8	2378-2387	recurring	_
15-9	2388-2395	problem	_
15-10	2396-2397	,	_
15-11	2398-2401	and	_
15-12	2402-2405	the	_
15-13	2406-2413	present	_
15-14	2414-2424	evaluation	_
15-15	2425-2427	of	_
15-16	2428-2431	the	_
15-17	2432-2436	role	_
15-18	2437-2439	of	_
15-19	2440-2446	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-20	2447-2449	in	_
15-21	2450-2453	its	_
15-22	2454-2463	treatment	_
15-23	2464-2469	holds	_
15-24	2470-2477	promise	_
15-25	2478-2481	for	_
15-26	2482-2493	identifying	_
15-27	2494-2495	a	_
15-28	2496-2499	way	_
15-29	2500-2502	to	_
15-30	2503-2510	prevent	_
15-31	2511-2518	relapse	_
15-32	2519-2520	.	_

Text=Trial registration ClinicalTrials.gov Identifier: NCT02486900, registered on 26 June 2015.
16-1	2521-2526	Trial	_
16-2	2527-2539	registration	_
16-3	2540-2558	ClinicalTrials.gov	_
16-4	2559-2569	Identifier	_
16-5	2570-2571	:	_
16-6	2572-2583	NCT02486900	_
16-7	2584-2585	,	_
16-8	2586-2596	registered	_
16-9	2597-2599	on	_
16-10	2600-2602	26	_
16-11	2603-2607	June	_
16-12	2608-2612	2015	_
16-13	2613-2614	.	_

Text=Electronic supplementary material The online version of this article (doi:10.1186/s13063-016-1607-7) contains supplementary material, which is available to authorized users.
17-1	2615-2625	Electronic	_
17-2	2626-2639	supplementary	_
17-3	2640-2648	material	_
17-4	2649-2652	The	_
17-5	2653-2659	online	_
17-6	2660-2667	version	_
17-7	2668-2670	of	_
17-8	2671-2675	this	_
17-9	2676-2683	article	_
17-10	2684-2685	(	_
17-11	2686-2715	doi:10.1186/s13063-016-1607-7	_
17-12	2716-2717	)	_
17-13	2718-2726	contains	_
17-14	2727-2740	supplementary	_
17-15	2741-2749	material	_
17-16	2750-2751	,	_
17-17	2752-2757	which	_
17-18	2758-2760	is	_
17-19	2761-2770	available	_
17-20	2771-2773	to	_
17-21	2774-2784	authorized	_
17-22	2785-2790	users	_
17-23	2791-2792	.	_

Text=Methods Ethical, safety, and privacy issues The Wales Research Ethics Committee 1 approved the research protocol (Ref: 14/WA/1172).
18-1	2793-2800	Methods	_
18-2	2801-2808	Ethical	_
18-3	2809-2810	,	_
18-4	2811-2817	safety	_
18-5	2818-2819	,	_
18-6	2820-2823	and	_
18-7	2824-2831	privacy	_
18-8	2832-2838	issues	_
18-9	2839-2842	The	_
18-10	2843-2848	Wales	_
18-11	2849-2857	Research	_
18-12	2858-2864	Ethics	_
18-13	2865-2874	Committee	_
18-14	2875-2876	1	_
18-15	2877-2885	approved	_
18-16	2886-2889	the	_
18-17	2890-2898	research	_
18-18	2899-2907	protocol	_
18-19	2908-2909	(	_
18-20	2910-2913	Ref	_
18-21	2914-2915	:	_
18-22	2916-2926	14/WA/1172	_
18-23	2927-2928	)	_
18-24	2929-2930	.	_

Text=Additionally, the Research and Development Committee at Cwm Taf University Health Board, Cardiff and Vale University Health Board, and Aneurin Bevan University Health Board approved the protocol.
19-1	2931-2943	Additionally	_
19-2	2944-2945	,	_
19-3	2946-2949	the	_
19-4	2950-2958	Research	_
19-5	2959-2962	and	_
19-6	2963-2974	Development	_
19-7	2975-2984	Committee	_
19-8	2985-2987	at	_
19-9	2988-2991	Cwm	_
19-10	2992-2995	Taf	_
19-11	2996-3006	University	_
19-12	3007-3013	Health	_
19-13	3014-3019	Board	_
19-14	3020-3021	,	_
19-15	3022-3029	Cardiff	_
19-16	3030-3033	and	_
19-17	3034-3038	Vale	_
19-18	3039-3049	University	_
19-19	3050-3056	Health	_
19-20	3057-3062	Board	_
19-21	3063-3064	,	_
19-22	3065-3068	and	_
19-23	3069-3076	Aneurin	_
19-24	3077-3082	Bevan	_
19-25	3083-3093	University	_
19-26	3094-3100	Health	_
19-27	3101-3106	Board	_
19-28	3107-3115	approved	_
19-29	3116-3119	the	_
19-30	3120-3128	protocol	_
19-31	3129-3130	.	_

Text=Plans for modifying the trial protocol are unforeseen; however, should they arise, approval will be sought from the relevant ethics committees.
20-1	3131-3136	Plans	_
20-2	3137-3140	for	_
20-3	3141-3150	modifying	_
20-4	3151-3154	the	_
20-5	3155-3160	trial	_
20-6	3161-3169	protocol	_
20-7	3170-3173	are	_
20-8	3174-3184	unforeseen	_
20-9	3185-3186	;	_
20-10	3187-3194	however	_
20-11	3195-3196	,	_
20-12	3197-3203	should	_
20-13	3204-3208	they	_
20-14	3209-3214	arise	_
20-15	3215-3216	,	_
20-16	3217-3225	approval	_
20-17	3226-3230	will	_
20-18	3231-3233	be	_
20-19	3234-3240	sought	_
20-20	3241-3245	from	_
20-21	3246-3249	the	_
20-22	3250-3258	relevant	_
20-23	3259-3265	ethics	_
20-24	3266-3276	committees	_
20-25	3277-3278	.	_

Text=Cardiff University as sponsor of the trial reserves the right to audit trial conduct should they have any concerns regarding conduct or safety.
21-1	3279-3286	Cardiff	_
21-2	3287-3297	University	_
21-3	3298-3300	as	_
21-4	3301-3308	sponsor	_
21-5	3309-3311	of	_
21-6	3312-3315	the	_
21-7	3316-3321	trial	_
21-8	3322-3330	reserves	_
21-9	3331-3334	the	_
21-10	3335-3340	right	_
21-11	3341-3343	to	_
21-12	3344-3349	audit	_
21-13	3350-3355	trial	_
21-14	3356-3363	conduct	_
21-15	3364-3370	should	_
21-16	3371-3375	they	_
21-17	3376-3380	have	_
21-18	3381-3384	any	_
21-19	3385-3393	concerns	_
21-20	3394-3403	regarding	_
21-21	3404-3411	conduct	_
21-22	3412-3414	or	_
21-23	3415-3421	safety	_
21-24	3422-3423	.	_

Text=The South East Wales Trials Unit (SEWTU) is providing oversight of trial conduct.
22-1	3424-3427	The	_
22-2	3428-3433	South	_
22-3	3434-3438	East	_
22-4	3439-3444	Wales	_
22-5	3445-3451	Trials	_
22-6	3452-3456	Unit	_
22-7	3457-3458	(	_
22-8	3459-3464	SEWTU	_
22-9	3465-3466	)	_
22-10	3467-3469	is	_
22-11	3470-3479	providing	_
22-12	3480-3489	oversight	_
22-13	3490-3492	of	_
22-14	3493-3498	trial	_
22-15	3499-3506	conduct	_
22-16	3507-3508	.	_

Text=The protocol was designed in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines for interventional trials (Additional File 1).
23-1	3509-3512	The	_
23-2	3513-3521	protocol	_
23-3	3522-3525	was	_
23-4	3526-3534	designed	_
23-5	3535-3537	in	_
23-6	3538-3548	accordance	_
23-7	3549-3553	with	_
23-8	3554-3557	the	_
23-9	3558-3564	SPIRIT	_
23-10	3565-3566	(	_
23-11	3567-3575	Standard	_
23-12	3576-3584	Protocol	_
23-13	3585-3590	Items	_
23-14	3591-3592	:	_
23-15	3593-3608	Recommendations	_
23-16	3609-3612	for	_
23-17	3613-3627	Interventional	_
23-18	3628-3634	Trials	_
23-19	3635-3636	)	_
23-20	3637-3647	guidelines	_
23-21	3648-3651	for	_
23-22	3652-3666	interventional	_
23-23	3667-3673	trials	_
23-24	3674-3675	(	_
23-25	3676-3686	Additional	_
23-26	3687-3691	File	_
23-27	3692-3693	1	_
23-28	3694-3695	)	_
23-29	3696-3697	.	_

Text=A magnetic resonance imaging (MRI) safety-screening questionnaire is used to screen potential participants for MRI scanning.
24-1	3698-3699	A	_
24-2	3700-3708	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-3	3709-3718	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-4	3719-3726	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-5	3727-3728	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-6	3729-3732	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-7	3733-3734	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-8	3735-3751	safety-screening	_
24-9	3752-3765	questionnaire	_
24-10	3766-3768	is	_
24-11	3769-3773	used	_
24-12	3774-3776	to	_
24-13	3777-3783	screen	_
24-14	3784-3793	potential	_
24-15	3794-3806	participants	_
24-16	3807-3810	for	_
24-17	3811-3814	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-18	3815-3823	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
24-19	3824-3825	.	_

Text=Patients who have contraindications for MRI scanning, such as metal implants in their bodies, are excluded.
25-1	3826-3834	Patients	_
25-2	3835-3838	who	_
25-3	3839-3843	have	_
25-4	3844-3861	contraindications	_
25-5	3862-3865	for	_
25-6	3866-3869	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-7	3870-3878	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
25-8	3879-3880	,	_
25-9	3881-3885	such	_
25-10	3886-3888	as	_
25-11	3889-3894	metal	_
25-12	3895-3903	implants	_
25-13	3904-3906	in	_
25-14	3907-3912	their	_
25-15	3913-3919	bodies	_
25-16	3920-3921	,	_
25-17	3922-3925	are	_
25-18	3926-3934	excluded	_
25-19	3935-3936	.	_

Text=All information and data obtained from participants during the course of the study will be kept confidential by the research team in accordance with the UK Data Protection Act 1998.
26-1	3937-3940	All	_
26-2	3941-3952	information	_
26-3	3953-3956	and	_
26-4	3957-3961	data	_
26-5	3962-3970	obtained	_
26-6	3971-3975	from	_
26-7	3976-3988	participants	_
26-8	3989-3995	during	_
26-9	3996-3999	the	_
26-10	4000-4006	course	_
26-11	4007-4009	of	_
26-12	4010-4013	the	_
26-13	4014-4019	study	_
26-14	4020-4024	will	_
26-15	4025-4027	be	_
26-16	4028-4032	kept	_
26-17	4033-4045	confidential	_
26-18	4046-4048	by	_
26-19	4049-4052	the	_
26-20	4053-4061	research	_
26-21	4062-4066	team	_
26-22	4067-4069	in	_
26-23	4070-4080	accordance	_
26-24	4081-4085	with	_
26-25	4086-4089	the	_
26-26	4090-4092	UK	_
26-27	4093-4097	Data	_
26-28	4098-4108	Protection	_
26-29	4109-4112	Act	_
26-30	4113-4117	1998	_
26-31	4118-4119	.	_

Text=Design The study is an unblinded, early-phase randomised feasibility trial that includes an experimental group and a control group of alcohol-dependent participants.
27-1	4120-4126	Design	_
27-2	4127-4130	The	_
27-3	4131-4136	study	_
27-4	4137-4139	is	_
27-5	4140-4142	an	_
27-6	4143-4152	unblinded	_
27-7	4153-4154	,	_
27-8	4155-4166	early-phase	_
27-9	4167-4177	randomised	_
27-10	4178-4189	feasibility	_
27-11	4190-4195	trial	_
27-12	4196-4200	that	_
27-13	4201-4209	includes	_
27-14	4210-4212	an	_
27-15	4213-4225	experimental	_
27-16	4226-4231	group	_
27-17	4232-4235	and	_
27-18	4236-4237	a	_
27-19	4238-4245	control	_
27-20	4246-4251	group	_
27-21	4252-4254	of	_
27-22	4255-4272	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
27-23	4273-4285	participants	_
27-24	4286-4287	.	_

Text=The experimental group (n = 25) receive fMRI NFT in addition to treatment as usual (TAU).
28-1	4288-4291	The	_
28-2	4292-4304	experimental	_
28-3	4305-4310	group	_
28-4	4311-4312	(	_
28-5	4313-4314	n	_
28-6	4315-4316	=	_
28-7	4317-4319	25	_
28-8	4320-4321	)	_
28-9	4322-4329	receive	_
28-10	4330-4334	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-11	4335-4338	NFT	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
28-12	4339-4341	in	_
28-13	4342-4350	addition	_
28-14	4351-4353	to	_
28-15	4354-4363	treatment	_
28-16	4364-4366	as	_
28-17	4367-4372	usual	_
28-18	4373-4374	(	_
28-19	4375-4378	TAU	_
28-20	4379-4380	)	_
28-21	4381-4382	.	_

Text=The control group (n = 25) receive only TAU.
29-1	4383-4386	The	_
29-2	4387-4394	control	_
29-3	4395-4400	group	_
29-4	4401-4402	(	_
29-5	4403-4404	n	_
29-6	4405-4406	=	_
29-7	4407-4409	25	_
29-8	4410-4411	)	_
29-9	4412-4419	receive	_
29-10	4420-4424	only	_
29-11	4425-4428	TAU	_
29-12	4429-4430	.	_

Text=Randomisation is balanced for time since detoxification (more than 3 months, less than 6 months).
30-1	4431-4444	Randomisation	_
30-2	4445-4447	is	_
30-3	4448-4456	balanced	_
30-4	4457-4460	for	_
30-5	4461-4465	time	_
30-6	4466-4471	since	_
30-7	4472-4486	detoxification	_
30-8	4487-4488	(	_
30-9	4489-4493	more	_
30-10	4494-4498	than	_
30-11	4499-4500	3	_
30-12	4501-4507	months	_
30-13	4508-4509	,	_
30-14	4510-4514	less	_
30-15	4515-4519	than	_
30-16	4520-4521	6	_
30-17	4522-4528	months	_
30-18	4529-4530	)	_
30-19	4531-4532	.	_

Text=The South East Wales Trials Unit is providing an online randomisation programme.
31-1	4533-4536	The	_
31-2	4537-4542	South	_
31-3	4543-4547	East	_
31-4	4548-4553	Wales	_
31-5	4554-4560	Trials	_
31-6	4561-4565	Unit	_
31-7	4566-4568	is	_
31-8	4569-4578	providing	_
31-9	4579-4581	an	_
31-10	4582-4588	online	_
31-11	4589-4602	randomisation	_
31-12	4603-4612	programme	_
31-13	4613-4614	.	_

Text=A flowchart showing the sequence of recruitment, assessment, and intervention is shown in Fig.
32-1	4615-4616	A	_
32-2	4617-4626	flowchart	_
32-3	4627-4634	showing	_
32-4	4635-4638	the	_
32-5	4639-4647	sequence	_
32-6	4648-4650	of	_
32-7	4651-4662	recruitment	_
32-8	4663-4664	,	_
32-9	4665-4675	assessment	_
32-10	4676-4677	,	_
32-11	4678-4681	and	_
32-12	4682-4694	intervention	_
32-13	4695-4697	is	_
32-14	4698-4703	shown	_
32-15	4704-4706	in	_
32-16	4707-4710	Fig	_
32-17	4711-4712	.	_

Text=1.
33-1	4713-4714	1	_
33-2	4715-4716	.	_

Text=A Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram of the study period is shown in Table 1.
34-1	4717-4718	A	_
34-2	4719-4727	Standard	_
34-3	4728-4736	Protocol	_
34-4	4737-4742	Items	_
34-5	4743-4744	:	_
34-6	4745-4760	Recommendations	_
34-7	4761-4764	for	_
34-8	4765-4779	Interventional	_
34-9	4780-4786	Trials	_
34-10	4787-4788	(	_
34-11	4789-4795	SPIRIT	_
34-12	4796-4797	)	_
34-13	4798-4805	diagram	_
34-14	4806-4808	of	_
34-15	4809-4812	the	_
34-16	4813-4818	study	_
34-17	4819-4825	period	_
34-18	4826-4828	is	_
34-19	4829-4834	shown	_
34-20	4835-4837	in	_
34-21	4838-4843	Table	_
34-22	4844-4845	1	_
34-23	4846-4847	.	_

Text=Participant eligibility, recruitment, and screening Eligible participants are alcohol-dependent patients who have successfully completed an inpatient detoxification programme 1 to 6 months before enrolment and are currently enrolled as outpatients.
35-1	4848-4859	Participant	_
35-2	4860-4871	eligibility	_
35-3	4872-4873	,	_
35-4	4874-4885	recruitment	_
35-5	4886-4887	,	_
35-6	4888-4891	and	_
35-7	4892-4901	screening	_
35-8	4902-4910	Eligible	_
35-9	4911-4923	participants	_
35-10	4924-4927	are	_
35-11	4928-4945	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
35-12	4946-4954	patients	_
35-13	4955-4958	who	_
35-14	4959-4963	have	_
35-15	4964-4976	successfully	_
35-16	4977-4986	completed	_
35-17	4987-4989	an	_
35-18	4990-4999	inpatient	_
35-19	5000-5014	detoxification	_
35-20	5015-5024	programme	_
35-21	5025-5026	1	_
35-22	5027-5029	to	_
35-23	5030-5031	6	_
35-24	5032-5038	months	_
35-25	5039-5045	before	_
35-26	5046-5055	enrolment	_
35-27	5056-5059	and	_
35-28	5060-5063	are	_
35-29	5064-5073	currently	_
35-30	5074-5082	enrolled	_
35-31	5083-5085	as	_
35-32	5086-5097	outpatients	_
35-33	5098-5099	.	_

Text=The programmes through which patients have been detoxified include those run by the Cwm Taf University Health Board, Cardiff and Vale University Health Board, and Aneurin Bevan University Health Board.
36-1	5100-5103	The	_
36-2	5104-5114	programmes	_
36-3	5115-5122	through	_
36-4	5123-5128	which	_
36-5	5129-5137	patients	_
36-6	5138-5142	have	_
36-7	5143-5147	been	_
36-8	5148-5158	detoxified	_
36-9	5159-5166	include	_
36-10	5167-5172	those	_
36-11	5173-5176	run	_
36-12	5177-5179	by	_
36-13	5180-5183	the	_
36-14	5184-5187	Cwm	_
36-15	5188-5191	Taf	_
36-16	5192-5202	University	_
36-17	5203-5209	Health	_
36-18	5210-5215	Board	_
36-19	5216-5217	,	_
36-20	5218-5225	Cardiff	_
36-21	5226-5229	and	_
36-22	5230-5234	Vale	_
36-23	5235-5245	University	_
36-24	5246-5252	Health	_
36-25	5253-5258	Board	_
36-26	5259-5260	,	_
36-27	5261-5264	and	_
36-28	5265-5272	Aneurin	_
36-29	5273-5278	Bevan	_
36-30	5279-5289	University	_
36-31	5290-5296	Health	_
36-32	5297-5302	Board	_
36-33	5303-5304	.	_

Text=Additional recruitment sites might be added at a later time.
37-1	5305-5315	Additional	_
37-2	5316-5327	recruitment	_
37-3	5328-5333	sites	_
37-4	5334-5339	might	_
37-5	5340-5342	be	_
37-6	5343-5348	added	_
37-7	5349-5351	at	_
37-8	5352-5353	a	_
37-9	5354-5359	later	_
37-10	5360-5364	time	_
37-11	5365-5366	.	_

Text=The TAU that patients receive includes psychological support, psychoeducation, and medical management of abstinence, for example with anticraving medication or disulfiram.
38-1	5367-5370	The	_
38-2	5371-5374	TAU	_
38-3	5375-5379	that	_
38-4	5380-5388	patients	_
38-5	5389-5396	receive	_
38-6	5397-5405	includes	_
38-7	5406-5419	psychological	_
38-8	5420-5427	support	_
38-9	5428-5429	,	_
38-10	5430-5445	psychoeducation	_
38-11	5446-5447	,	_
38-12	5448-5451	and	_
38-13	5452-5459	medical	_
38-14	5460-5470	management	_
38-15	5471-5473	of	_
38-16	5474-5484	abstinence	_
38-17	5485-5486	,	_
38-18	5487-5490	for	_
38-19	5491-5498	example	_
38-20	5499-5503	with	_
38-21	5504-5515	anticraving	_
38-22	5516-5526	medication	_
38-23	5527-5529	or	_
38-24	5530-5540	disulfiram	_
38-25	5541-5542	.	_

Text=Participants are randomly assigned to (1) a control group who continue to receive only TAU, or (2) an experimental group who receive rtfMRI NFT in addition to TAU.
39-1	5543-5555	Participants	_
39-2	5556-5559	are	_
39-3	5560-5568	randomly	_
39-4	5569-5577	assigned	_
39-5	5578-5580	to	_
39-6	5581-5582	(	_
39-7	5583-5584	1	_
39-8	5585-5586	)	_
39-9	5587-5588	a	_
39-10	5589-5596	control	_
39-11	5597-5602	group	_
39-12	5603-5606	who	_
39-13	5607-5615	continue	_
39-14	5616-5618	to	_
39-15	5619-5626	receive	_
39-16	5627-5631	only	_
39-17	5632-5635	TAU	_
39-18	5636-5637	,	_
39-19	5638-5640	or	_
39-20	5641-5642	(	_
39-21	5643-5644	2	_
39-22	5645-5646	)	_
39-23	5647-5649	an	_
39-24	5650-5662	experimental	_
39-25	5663-5668	group	_
39-26	5669-5672	who	_
39-27	5673-5680	receive	_
39-28	5681-5687	rtfMRI	_
39-29	5688-5691	NFT	_
39-30	5692-5694	in	_
39-31	5695-5703	addition	_
39-32	5704-5706	to	_
39-33	5707-5710	TAU	_
39-34	5711-5712	.	_

Text=Potential participants ’ diagnosis of alcohol dependence (International Classification of Diseases, tenth edition (ICD-10): F102) is confirmed by inspection of their clinical records.
40-1	5713-5722	Potential	_
40-2	5723-5735	participants	_
40-3	5736-5737	’	_
40-4	5738-5747	diagnosis	_
40-5	5748-5750	of	_
40-6	5751-5758	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
40-7	5759-5769	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
40-8	5770-5771	(	_
40-9	5772-5785	International	_
40-10	5786-5800	Classification	_
40-11	5801-5803	of	_
40-12	5804-5812	Diseases	_
40-13	5813-5814	,	_
40-14	5815-5820	tenth	_
40-15	5821-5828	edition	_
40-16	5829-5830	(	_
40-17	5831-5837	ICD-10	_
40-18	5838-5839	)	_
40-19	5840-5841	:	_
40-20	5842-5846	F102	_
40-21	5847-5848	)	_
40-22	5849-5851	is	_
40-23	5852-5861	confirmed	_
40-24	5862-5864	by	_
40-25	5865-5875	inspection	_
40-26	5876-5878	of	_
40-27	5879-5884	their	_
40-28	5885-5893	clinical	_
40-29	5894-5901	records	_
40-30	5902-5903	.	_

Text=Patients meeting this criterion are initially identified and approached to judge their interest in and suitability for participating in the study.
41-1	5904-5912	Patients	_
41-2	5913-5920	meeting	_
41-3	5921-5925	this	_
41-4	5926-5935	criterion	_
41-5	5936-5939	are	_
41-6	5940-5949	initially	_
41-7	5950-5960	identified	_
41-8	5961-5964	and	_
41-9	5965-5975	approached	_
41-10	5976-5978	to	_
41-11	5979-5984	judge	_
41-12	5985-5990	their	_
41-13	5991-5999	interest	_
41-14	6000-6002	in	_
41-15	6003-6006	and	_
41-16	6007-6018	suitability	_
41-17	6019-6022	for	_
41-18	6023-6036	participating	_
41-19	6037-6039	in	_
41-20	6040-6043	the	_
41-21	6044-6049	study	_
41-22	6050-6051	.	_

Text=These contacts are made either by (1) clinicians who are directly involved in the care of the patients, or (2) staff from the Health and Care Research Workforce in Wales.
42-1	6052-6057	These	_
42-2	6058-6066	contacts	_
42-3	6067-6070	are	_
42-4	6071-6075	made	_
42-5	6076-6082	either	_
42-6	6083-6085	by	_
42-7	6086-6087	(	_
42-8	6088-6089	1	_
42-9	6090-6091	)	_
42-10	6092-6102	clinicians	_
42-11	6103-6106	who	_
42-12	6107-6110	are	_
42-13	6111-6119	directly	_
42-14	6120-6128	involved	_
42-15	6129-6131	in	_
42-16	6132-6135	the	_
42-17	6136-6140	care	_
42-18	6141-6143	of	_
42-19	6144-6147	the	_
42-20	6148-6156	patients	_
42-21	6157-6158	,	_
42-22	6159-6161	or	_
42-23	6162-6163	(	_
42-24	6164-6165	2	_
42-25	6166-6167	)	_
42-26	6168-6173	staff	_
42-27	6174-6178	from	_
42-28	6179-6182	the	_
42-29	6183-6189	Health	_
42-30	6190-6193	and	_
42-31	6194-6198	Care	_
42-32	6199-6207	Research	_
42-33	6208-6217	Workforce	_
42-34	6218-6220	in	_
42-35	6221-6226	Wales	_
42-36	6227-6228	.	_

Text=Patients who are identified as suitable for the study are either invited personally by their primary clinician or they are sent a letter of invitation by their clinical team.
43-1	6229-6237	Patients	_
43-2	6238-6241	who	_
43-3	6242-6245	are	_
43-4	6246-6256	identified	_
43-5	6257-6259	as	_
43-6	6260-6268	suitable	_
43-7	6269-6272	for	_
43-8	6273-6276	the	_
43-9	6277-6282	study	_
43-10	6283-6286	are	_
43-11	6287-6293	either	_
43-12	6294-6301	invited	_
43-13	6302-6312	personally	_
43-14	6313-6315	by	_
43-15	6316-6321	their	_
43-16	6322-6329	primary	_
43-17	6330-6339	clinician	_
43-18	6340-6342	or	_
43-19	6343-6347	they	_
43-20	6348-6351	are	_
43-21	6352-6356	sent	_
43-22	6357-6358	a	_
43-23	6359-6365	letter	_
43-24	6366-6368	of	_
43-25	6369-6379	invitation	_
43-26	6380-6382	by	_
43-27	6383-6388	their	_
43-28	6389-6397	clinical	_
43-29	6398-6402	team	_
43-30	6403-6404	.	_

Text=Patients are also offered the opportunity to obtain more information about the study and to ask questions at informational events called open days, which are organised at the recruitment sites.
44-1	6405-6413	Patients	_
44-2	6414-6417	are	_
44-3	6418-6422	also	_
44-4	6423-6430	offered	_
44-5	6431-6434	the	_
44-6	6435-6446	opportunity	_
44-7	6447-6449	to	_
44-8	6450-6456	obtain	_
44-9	6457-6461	more	_
44-10	6462-6473	information	_
44-11	6474-6479	about	_
44-12	6480-6483	the	_
44-13	6484-6489	study	_
44-14	6490-6493	and	_
44-15	6494-6496	to	_
44-16	6497-6500	ask	_
44-17	6501-6510	questions	_
44-18	6511-6513	at	_
44-19	6514-6527	informational	_
44-20	6528-6534	events	_
44-21	6535-6541	called	_
44-22	6542-6546	open	_
44-23	6547-6551	days	_
44-24	6552-6553	,	_
44-25	6554-6559	which	_
44-26	6560-6563	are	_
44-27	6564-6573	organised	_
44-28	6574-6576	at	_
44-29	6577-6580	the	_
44-30	6581-6592	recruitment	_
44-31	6593-6598	sites	_
44-32	6599-6600	.	_

Text=During the open days, one or more members of the research team present details about the procedures and practicalities of the study (e.g.
45-1	6601-6607	During	_
45-2	6608-6611	the	_
45-3	6612-6616	open	_
45-4	6617-6621	days	_
45-5	6622-6623	,	_
45-6	6624-6627	one	_
45-7	6628-6630	or	_
45-8	6631-6635	more	_
45-9	6636-6643	members	_
45-10	6644-6646	of	_
45-11	6647-6650	the	_
45-12	6651-6659	research	_
45-13	6660-6664	team	_
45-14	6665-6672	present	_
45-15	6673-6680	details	_
45-16	6681-6686	about	_
45-17	6687-6690	the	_
45-18	6691-6701	procedures	_
45-19	6702-6705	and	_
45-20	6706-6720	practicalities	_
45-21	6721-6723	of	_
45-22	6724-6727	the	_
45-23	6728-6733	study	_
45-24	6734-6735	(	_
45-25	6736-6739	e.g	_
45-26	6740-6741	.	_

Text=scanning procedures, questionnaires that are being used).
46-1	6742-6750	scanning	_
46-2	6751-6761	procedures	_
46-3	6762-6763	,	_
46-4	6764-6778	questionnaires	_
46-5	6779-6783	that	_
46-6	6784-6787	are	_
46-7	6788-6793	being	_
46-8	6794-6798	used	_
46-9	6799-6800	)	_
46-10	6801-6802	.	_

Text=The Mini International Neuropsychiatric Interview (MINI) is a short, structured interview for diagnosing psychiatric disorders based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and ICD criteria.
47-1	6803-6806	The	_
47-2	6807-6811	Mini	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-3	6812-6825	International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-4	6826-6842	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-5	6843-6852	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-6	6853-6854	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-7	6855-6859	MINI	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-8	6860-6861	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
47-9	6862-6864	is	_
47-10	6865-6866	a	_
47-11	6867-6872	short	_
47-12	6873-6874	,	_
47-13	6875-6885	structured	_
47-14	6886-6895	interview	_
47-15	6896-6899	for	_
47-16	6900-6910	diagnosing	_
47-17	6911-6922	psychiatric	_
47-18	6923-6932	disorders	_
47-19	6933-6938	based	_
47-20	6939-6941	on	_
47-21	6942-6952	Diagnostic	_
47-22	6953-6956	and	_
47-23	6957-6968	Statistical	_
47-24	6969-6975	Manual	_
47-25	6976-6978	of	_
47-26	6979-6985	Mental	_
47-27	6986-6995	Disorders	_
47-28	6996-6997	,	_
47-29	6998-7004	fourth	_
47-30	7005-7012	edition	_
47-31	7013-7014	(	_
47-32	7015-7021	DSM-IV	_
47-33	7022-7023	)	_
47-34	7024-7027	and	_
47-35	7028-7031	ICD	_
47-36	7032-7040	criteria	_
47-37	7041-7042	.	_

Text=Only the psychosis section of the MINI is administered.
48-1	7043-7047	Only	_
48-2	7048-7051	the	_
48-3	7052-7061	psychosis	_
48-4	7062-7069	section	_
48-5	7070-7072	of	_
48-6	7073-7076	the	_
48-7	7077-7081	MINI	_
48-8	7082-7084	is	_
48-9	7085-7097	administered	_
48-10	7098-7099	.	_

Text=Patients identified as having a history of a psychotic disorder not related to alcohol dependence are excluded from participating The Wechsler Abbreviated Intelligence Scale (WASI-II) provides a global measure of patients ’ level of intellectual functioning.
49-1	7100-7108	Patients	_
49-2	7109-7119	identified	_
49-3	7120-7122	as	_
49-4	7123-7129	having	_
49-5	7130-7131	a	_
49-6	7132-7139	history	_
49-7	7140-7142	of	_
49-8	7143-7144	a	_
49-9	7145-7154	psychotic	_
49-10	7155-7163	disorder	_
49-11	7164-7167	not	_
49-12	7168-7175	related	_
49-13	7176-7178	to	_
49-14	7179-7186	alcohol	_
49-15	7187-7197	dependence	_
49-16	7198-7201	are	_
49-17	7202-7210	excluded	_
49-18	7211-7215	from	_
49-19	7216-7229	participating	_
49-20	7230-7233	The	_
49-21	7234-7242	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-22	7243-7254	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-23	7255-7267	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-24	7268-7273	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-25	7274-7275	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-26	7276-7283	WASI-II	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-27	7284-7285	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
49-28	7286-7294	provides	_
49-29	7295-7296	a	_
49-30	7297-7303	global	_
49-31	7304-7311	measure	_
49-32	7312-7314	of	_
49-33	7315-7323	patients	_
49-34	7324-7325	’	_
49-35	7326-7331	level	_
49-36	7332-7334	of	_
49-37	7335-7347	intellectual	_
49-38	7348-7359	functioning	_
49-39	7360-7361	.	_

Text=Participants with an IQ below 70 are excluded because they would likely find the experimental tasks too difficult to complete An in-house drug-use questionnaire measures participants ’ use of illicit substances.
50-1	7362-7374	Participants	_
50-2	7375-7379	with	_
50-3	7380-7382	an	_
50-4	7383-7385	IQ	_
50-5	7386-7391	below	_
50-6	7392-7394	70	_
50-7	7395-7398	are	_
50-8	7399-7407	excluded	_
50-9	7408-7415	because	_
50-10	7416-7420	they	_
50-11	7421-7426	would	_
50-12	7427-7433	likely	_
50-13	7434-7438	find	_
50-14	7439-7442	the	_
50-15	7443-7455	experimental	_
50-16	7456-7461	tasks	_
50-17	7462-7465	too	_
50-18	7466-7475	difficult	_
50-19	7476-7478	to	_
50-20	7479-7487	complete	_
50-21	7488-7490	An	_
50-22	7491-7499	in-house	_
50-23	7500-7508	drug-use	_
50-24	7509-7522	questionnaire	_
50-25	7523-7531	measures	_
50-26	7532-7544	participants	_
50-27	7545-7546	’	_
50-28	7547-7550	use	_
50-29	7551-7553	of	_
50-30	7554-7561	illicit	_
50-31	7562-7572	substances	_
50-32	7573-7574	.	_

Text=Patients who have on-going regular use of illicit drugs, except for cannabis, are excluded The Alcohol Timeline Followback (TLFB) Questionnaire is used to determine whether patients have drunk alcohol since their discharge from their detoxification programme.
51-1	7575-7583	Patients	_
51-2	7584-7587	who	_
51-3	7588-7592	have	_
51-4	7593-7601	on-going	_
51-5	7602-7609	regular	_
51-6	7610-7613	use	_
51-7	7614-7616	of	_
51-8	7617-7624	illicit	_
51-9	7625-7630	drugs	_
51-10	7631-7632	,	_
51-11	7633-7639	except	_
51-12	7640-7643	for	_
51-13	7644-7652	cannabis	_
51-14	7653-7654	,	_
51-15	7655-7658	are	_
51-16	7659-7667	excluded	_
51-17	7668-7671	The	_
51-18	7672-7679	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-19	7680-7688	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-20	7689-7699	Followback	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-21	7700-7701	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-22	7702-7706	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-23	7707-7708	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-24	7709-7722	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
51-25	7723-7725	is	_
51-26	7726-7730	used	_
51-27	7731-7733	to	_
51-28	7734-7743	determine	_
51-29	7744-7751	whether	_
51-30	7752-7760	patients	_
51-31	7761-7765	have	_
51-32	7766-7771	drunk	_
51-33	7772-7779	alcohol	_
51-34	7780-7785	since	_
51-35	7786-7791	their	_
51-36	7792-7801	discharge	_
51-37	7802-7806	from	_
51-38	7807-7812	their	_
51-39	7813-7827	detoxification	_
51-40	7828-7837	programme	_
51-41	7838-7839	.	_

Text=Patients who have drunk any alcohol are excluded Once suitable patients have indicated an interest in participating in the study, they are invited to visit either one of the community alcohol and drug clinics or our research laboratory at Cardiff University.
52-1	7840-7848	Patients	_
52-2	7849-7852	who	_
52-3	7853-7857	have	_
52-4	7858-7863	drunk	_
52-5	7864-7867	any	_
52-6	7868-7875	alcohol	_
52-7	7876-7879	are	_
52-8	7880-7888	excluded	_
52-9	7889-7893	Once	_
52-10	7894-7902	suitable	_
52-11	7903-7911	patients	_
52-12	7912-7916	have	_
52-13	7917-7926	indicated	_
52-14	7927-7929	an	_
52-15	7930-7938	interest	_
52-16	7939-7941	in	_
52-17	7942-7955	participating	_
52-18	7956-7958	in	_
52-19	7959-7962	the	_
52-20	7963-7968	study	_
52-21	7969-7970	,	_
52-22	7971-7975	they	_
52-23	7976-7979	are	_
52-24	7980-7987	invited	_
52-25	7988-7990	to	_
52-26	7991-7996	visit	_
52-27	7997-8003	either	_
52-28	8004-8007	one	_
52-29	8008-8010	of	_
52-30	8011-8014	the	_
52-31	8015-8024	community	_
52-32	8025-8032	alcohol	_
52-33	8033-8036	and	_
52-34	8037-8041	drug	_
52-35	8042-8049	clinics	_
52-36	8050-8052	or	_
52-37	8053-8056	our	_
52-38	8057-8065	research	_
52-39	8066-8076	laboratory	_
52-40	8077-8079	at	_
52-41	8080-8087	Cardiff	_
52-42	8088-8098	University	_
52-43	8099-8100	.	_

Text=In either case, a research officer will give patients an information sheet about the study procedure, and will also ask participants to provide written informed consent to participate in the study (see Additional Files 2 and 3).
53-1	8101-8103	In	_
53-2	8104-8110	either	_
53-3	8111-8115	case	_
53-4	8116-8117	,	_
53-5	8118-8119	a	_
53-6	8120-8128	research	_
53-7	8129-8136	officer	_
53-8	8137-8141	will	_
53-9	8142-8146	give	_
53-10	8147-8155	patients	_
53-11	8156-8158	an	_
53-12	8159-8170	information	_
53-13	8171-8176	sheet	_
53-14	8177-8182	about	_
53-15	8183-8186	the	_
53-16	8187-8192	study	_
53-17	8193-8202	procedure	_
53-18	8203-8204	,	_
53-19	8205-8208	and	_
53-20	8209-8213	will	_
53-21	8214-8218	also	_
53-22	8219-8222	ask	_
53-23	8223-8235	participants	_
53-24	8236-8238	to	_
53-25	8239-8246	provide	_
53-26	8247-8254	written	_
53-27	8255-8263	informed	_
53-28	8264-8271	consent	_
53-29	8272-8274	to	_
53-30	8275-8286	participate	_
53-31	8287-8289	in	_
53-32	8290-8293	the	_
53-33	8294-8299	study	_
53-34	8300-8301	(	_
53-35	8302-8305	see	_
53-36	8306-8316	Additional	_
53-37	8317-8322	Files	_
53-38	8323-8324	2	_
53-39	8325-8328	and	_
53-40	8329-8330	3	_
53-41	8331-8332	)	_
53-42	8333-8334	.	_

Text=If consent is obtained, participants are asked to complete several screening assessments as follows: Participants are informed that they are free to withdraw from the study at any time.
54-1	8335-8337	If	_
54-2	8338-8345	consent	_
54-3	8346-8348	is	_
54-4	8349-8357	obtained	_
54-5	8358-8359	,	_
54-6	8360-8372	participants	_
54-7	8373-8376	are	_
54-8	8377-8382	asked	_
54-9	8383-8385	to	_
54-10	8386-8394	complete	_
54-11	8395-8402	several	_
54-12	8403-8412	screening	_
54-13	8413-8424	assessments	_
54-14	8425-8427	as	_
54-15	8428-8435	follows	_
54-16	8436-8437	:	_
54-17	8438-8450	Participants	_
54-18	8451-8454	are	_
54-19	8455-8463	informed	_
54-20	8464-8468	that	_
54-21	8469-8473	they	_
54-22	8474-8477	are	_
54-23	8478-8482	free	_
54-24	8483-8485	to	_
54-25	8486-8494	withdraw	_
54-26	8495-8499	from	_
54-27	8500-8503	the	_
54-28	8504-8509	study	_
54-29	8510-8512	at	_
54-30	8513-8516	any	_
54-31	8517-8521	time	_
54-32	8522-8523	.	_

Text=Baseline assessment During the baseline assessment, participants complete the following instruments: a demographic questionnaire (which asks about participants ’ age, gender, level of education, and socioeconomic status); a National Health Service (NHS) resources utilisation questionnaire (which asks about the use of prescription medications and treatment services); and various standardised measures which are shown in Table 2.
55-1	8524-8532	Baseline	_
55-2	8533-8543	assessment	_
55-3	8544-8550	During	_
55-4	8551-8554	the	_
55-5	8555-8563	baseline	_
55-6	8564-8574	assessment	_
55-7	8575-8576	,	_
55-8	8577-8589	participants	_
55-9	8590-8598	complete	_
55-10	8599-8602	the	_
55-11	8603-8612	following	_
55-12	8613-8624	instruments	_
55-13	8625-8626	:	_
55-14	8627-8628	a	_
55-15	8629-8640	demographic	_
55-16	8641-8654	questionnaire	_
55-17	8655-8656	(	_
55-18	8657-8662	which	_
55-19	8663-8667	asks	_
55-20	8668-8673	about	_
55-21	8674-8686	participants	_
55-22	8687-8688	’	_
55-23	8689-8692	age	_
55-24	8693-8694	,	_
55-25	8695-8701	gender	_
55-26	8702-8703	,	_
55-27	8704-8709	level	_
55-28	8710-8712	of	_
55-29	8713-8722	education	_
55-30	8723-8724	,	_
55-31	8725-8728	and	_
55-32	8729-8742	socioeconomic	_
55-33	8743-8749	status	_
55-34	8750-8751	)	_
55-35	8752-8753	;	_
55-36	8754-8755	a	_
55-37	8756-8764	National	_
55-38	8765-8771	Health	_
55-39	8772-8779	Service	_
55-40	8780-8781	(	_
55-41	8782-8785	NHS	_
55-42	8786-8787	)	_
55-43	8788-8797	resources	_
55-44	8798-8809	utilisation	_
55-45	8810-8823	questionnaire	_
55-46	8824-8825	(	_
55-47	8826-8831	which	_
55-48	8832-8836	asks	_
55-49	8837-8842	about	_
55-50	8843-8846	the	_
55-51	8847-8850	use	_
55-52	8851-8853	of	_
55-53	8854-8866	prescription	_
55-54	8867-8878	medications	_
55-55	8879-8882	and	_
55-56	8883-8892	treatment	_
55-57	8893-8901	services	_
55-58	8902-8903	)	_
55-59	8904-8905	;	_
55-60	8906-8909	and	_
55-61	8910-8917	various	_
55-62	8918-8930	standardised	_
55-63	8931-8939	measures	_
55-64	8940-8945	which	_
55-65	8946-8949	are	_
55-66	8950-8955	shown	_
55-67	8956-8958	in	_
55-68	8959-8964	Table	_
55-69	8965-8966	2	_
55-70	8967-8968	.	_

Text=Patients are randomised after the baseline session.
56-1	8969-8977	Patients	_
56-2	8978-8981	are	_
56-3	8982-8992	randomised	_
56-4	8993-8998	after	_
56-5	8999-9002	the	_
56-6	9003-9011	baseline	_
56-7	9012-9019	session	_
56-8	9020-9021	.	_

Text=Assessment at NFT sessions At each of the six NFT sessions across 4 months, patients in the experimental group complete the Drinking Urges Questionnaire (before and after the MRI scan), a self-rating of craving during the scanning session, the Alcohol TLFB (only after the last training session and covering the period from the baseline assessment to the present), the Alcohol Stroop Test (only after the last training session); the OCDS (only after the last training session); the HADS (only at the last training session); the BDI (only at the last training session); a debriefing interview questionnaire to identify strategies that participants used to down-regulate their brain reactions to alcohol stimuli (and up-regulate their brain responses to other goal-related pictures), their general experience with the procedure, and any adverse reactions that they might have experienced.
57-1	9022-9032	Assessment	_
57-2	9033-9035	at	_
57-3	9036-9039	NFT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-4	9040-9048	sessions	_
57-5	9049-9051	At	_
57-6	9052-9056	each	_
57-7	9057-9059	of	_
57-8	9060-9063	the	_
57-9	9064-9067	six	_
57-10	9068-9071	NFT	_
57-11	9072-9080	sessions	_
57-12	9081-9087	across	_
57-13	9088-9089	4	_
57-14	9090-9096	months	_
57-15	9097-9098	,	_
57-16	9099-9107	patients	_
57-17	9108-9110	in	_
57-18	9111-9114	the	_
57-19	9115-9127	experimental	_
57-20	9128-9133	group	_
57-21	9134-9142	complete	_
57-22	9143-9146	the	_
57-23	9147-9155	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
57-24	9156-9161	Urges	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
57-25	9162-9175	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
57-26	9176-9177	(	_
57-27	9178-9184	before	_
57-28	9185-9188	and	_
57-29	9189-9194	after	_
57-30	9195-9198	the	_
57-31	9199-9202	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
57-32	9203-9207	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
57-33	9208-9209	)	_
57-34	9210-9211	,	_
57-35	9212-9213	a	_
57-36	9214-9225	self-rating	_
57-37	9226-9228	of	_
57-38	9229-9236	craving	_
57-39	9237-9243	during	_
57-40	9244-9247	the	_
57-41	9248-9256	scanning	_
57-42	9257-9264	session	_
57-43	9265-9266	,	_
57-44	9267-9270	the	_
57-45	9271-9278	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
57-46	9279-9283	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
57-47	9284-9285	(	_
57-48	9286-9290	only	_
57-49	9291-9296	after	_
57-50	9297-9300	the	_
57-51	9301-9305	last	_
57-52	9306-9314	training	_
57-53	9315-9322	session	_
57-54	9323-9326	and	_
57-55	9327-9335	covering	_
57-56	9336-9339	the	_
57-57	9340-9346	period	_
57-58	9347-9351	from	_
57-59	9352-9355	the	_
57-60	9356-9364	baseline	_
57-61	9365-9375	assessment	_
57-62	9376-9378	to	_
57-63	9379-9382	the	_
57-64	9383-9390	present	_
57-65	9391-9392	)	_
57-66	9393-9394	,	_
57-67	9395-9398	the	_
57-68	9399-9406	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
57-69	9407-9413	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
57-70	9414-9418	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
57-71	9419-9420	(	_
57-72	9421-9425	only	_
57-73	9426-9431	after	_
57-74	9432-9435	the	_
57-75	9436-9440	last	_
57-76	9441-9449	training	_
57-77	9450-9457	session	_
57-78	9458-9459	)	_
57-79	9460-9461	;	_
57-80	9462-9465	the	_
57-81	9466-9470	OCDS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-82	9471-9472	(	_
57-83	9473-9477	only	_
57-84	9478-9483	after	_
57-85	9484-9487	the	_
57-86	9488-9492	last	_
57-87	9493-9501	training	_
57-88	9502-9509	session	_
57-89	9510-9511	)	_
57-90	9512-9513	;	_
57-91	9514-9517	the	_
57-92	9518-9522	HADS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-93	9523-9524	(	_
57-94	9525-9529	only	_
57-95	9530-9532	at	_
57-96	9533-9536	the	_
57-97	9537-9541	last	_
57-98	9542-9550	training	_
57-99	9551-9558	session	_
57-100	9559-9560	)	_
57-101	9561-9562	;	_
57-102	9563-9566	the	_
57-103	9567-9570	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
57-104	9571-9572	(	_
57-105	9573-9577	only	_
57-106	9578-9580	at	_
57-107	9581-9584	the	_
57-108	9585-9589	last	_
57-109	9590-9598	training	_
57-110	9599-9606	session	_
57-111	9607-9608	)	_
57-112	9609-9610	;	_
57-113	9611-9612	a	_
57-114	9613-9623	debriefing	_
57-115	9624-9633	interview	_
57-116	9634-9647	questionnaire	_
57-117	9648-9650	to	_
57-118	9651-9659	identify	_
57-119	9660-9670	strategies	_
57-120	9671-9675	that	_
57-121	9676-9688	participants	_
57-122	9689-9693	used	_
57-123	9694-9696	to	_
57-124	9697-9710	down-regulate	_
57-125	9711-9716	their	_
57-126	9717-9722	brain	_
57-127	9723-9732	reactions	_
57-128	9733-9735	to	_
57-129	9736-9743	alcohol	_
57-130	9744-9751	stimuli	_
57-131	9752-9753	(	_
57-132	9754-9757	and	_
57-133	9758-9769	up-regulate	_
57-134	9770-9775	their	_
57-135	9776-9781	brain	_
57-136	9782-9791	responses	_
57-137	9792-9794	to	_
57-138	9795-9800	other	_
57-139	9801-9813	goal-related	_
57-140	9814-9822	pictures	_
57-141	9823-9824	)	_
57-142	9825-9826	,	_
57-143	9827-9832	their	_
57-144	9833-9840	general	_
57-145	9841-9851	experience	_
57-146	9852-9856	with	_
57-147	9857-9860	the	_
57-148	9861-9870	procedure	_
57-149	9871-9872	,	_
57-150	9873-9876	and	_
57-151	9877-9880	any	_
57-152	9881-9888	adverse	_
57-153	9889-9898	reactions	_
57-154	9899-9903	that	_
57-155	9904-9908	they	_
57-156	9909-9914	might	_
57-157	9915-9919	have	_
57-158	9920-9931	experienced	_
57-159	9932-9933	.	_

Text=Four-month assessment of the control group Four months after their baseline assessment, patients in the control group complete the Alcohol TLFB (covering the period from the baseline assessment to the present), the NHS resource utilisation questionnaire, the Drinking Urges Questionnaire, the Alcohol Stroop Test, the OCDS, and the POMS.
58-1	9934-9944	Four-month	_
58-2	9945-9955	assessment	_
58-3	9956-9958	of	_
58-4	9959-9962	the	_
58-5	9963-9970	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
58-6	9971-9976	group	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
58-7	9977-9981	Four	_
58-8	9982-9988	months	_
58-9	9989-9994	after	_
58-10	9995-10000	their	_
58-11	10001-10009	baseline	_
58-12	10010-10020	assessment	_
58-13	10021-10022	,	_
58-14	10023-10031	patients	_
58-15	10032-10034	in	_
58-16	10035-10038	the	_
58-17	10039-10046	control	_
58-18	10047-10052	group	_
58-19	10053-10061	complete	_
58-20	10062-10065	the	_
58-21	10066-10073	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
58-22	10074-10078	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
58-23	10079-10080	(	_
58-24	10081-10089	covering	_
58-25	10090-10093	the	_
58-26	10094-10100	period	_
58-27	10101-10105	from	_
58-28	10106-10109	the	_
58-29	10110-10118	baseline	_
58-30	10119-10129	assessment	_
58-31	10130-10132	to	_
58-32	10133-10136	the	_
58-33	10137-10144	present	_
58-34	10145-10146	)	_
58-35	10147-10148	,	_
58-36	10149-10152	the	_
58-37	10153-10156	NHS	_
58-38	10157-10165	resource	_
58-39	10166-10177	utilisation	_
58-40	10178-10191	questionnaire	_
58-41	10192-10193	,	_
58-42	10194-10197	the	_
58-43	10198-10206	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
58-44	10207-10212	Urges	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
58-45	10213-10226	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
58-46	10227-10228	,	_
58-47	10229-10232	the	_
58-48	10233-10240	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
58-49	10241-10247	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
58-50	10248-10252	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
58-51	10253-10254	,	_
58-52	10255-10258	the	_
58-53	10259-10263	OCDS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
58-54	10264-10265	,	_
58-55	10266-10269	and	_
58-56	10270-10273	the	_
58-57	10274-10278	POMS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
58-58	10279-10280	.	_

Text=Follow-up assessments Eight and 12 months after the baseline assessment, both the experimental group and the control group are administered the Alcohol TLFB (covering the period from the previous assessment to the present), the NHS resource utilisation questionnaire, the Drinking Urges Questionnaire, the Alcohol Stroop Test, the OCDS, the POMS, the HADS, and the BDI.
59-1	10281-10290	Follow-up	_
59-2	10291-10302	assessments	_
59-3	10303-10308	Eight	_
59-4	10309-10312	and	_
59-5	10313-10315	12	_
59-6	10316-10322	months	_
59-7	10323-10328	after	_
59-8	10329-10332	the	_
59-9	10333-10341	baseline	_
59-10	10342-10352	assessment	_
59-11	10353-10354	,	_
59-12	10355-10359	both	_
59-13	10360-10363	the	_
59-14	10364-10376	experimental	_
59-15	10377-10382	group	_
59-16	10383-10386	and	_
59-17	10387-10390	the	_
59-18	10391-10398	control	_
59-19	10399-10404	group	_
59-20	10405-10408	are	_
59-21	10409-10421	administered	_
59-22	10422-10425	the	_
59-23	10426-10433	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
59-24	10434-10438	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
59-25	10439-10440	(	_
59-26	10441-10449	covering	_
59-27	10450-10453	the	_
59-28	10454-10460	period	_
59-29	10461-10465	from	_
59-30	10466-10469	the	_
59-31	10470-10478	previous	_
59-32	10479-10489	assessment	_
59-33	10490-10492	to	_
59-34	10493-10496	the	_
59-35	10497-10504	present	_
59-36	10505-10506	)	_
59-37	10507-10508	,	_
59-38	10509-10512	the	_
59-39	10513-10516	NHS	_
59-40	10517-10525	resource	_
59-41	10526-10537	utilisation	_
59-42	10538-10551	questionnaire	_
59-43	10552-10553	,	_
59-44	10554-10557	the	_
59-45	10558-10566	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
59-46	10567-10572	Urges	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
59-47	10573-10586	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
59-48	10587-10588	,	_
59-49	10589-10592	the	_
59-50	10593-10600	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-51	10601-10607	Stroop	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-52	10608-10612	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
59-53	10613-10614	,	_
59-54	10615-10618	the	_
59-55	10619-10623	OCDS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
59-56	10624-10625	,	_
59-57	10626-10629	the	_
59-58	10630-10634	POMS	_
59-59	10635-10636	,	_
59-60	10637-10640	the	_
59-61	10641-10645	HADS	_
59-62	10646-10647	,	_
59-63	10648-10651	and	_
59-64	10652-10655	the	_
59-65	10656-10659	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
59-66	10660-10661	.	_

Text=BRAINTRAIN core outcome measures Some of the assessment instruments named above are part of the BRAINTRAIN core outcome measures, i.e.
60-1	10662-10672	BRAINTRAIN	_
60-2	10673-10677	core	_
60-3	10678-10685	outcome	_
60-4	10686-10694	measures	_
60-5	10695-10699	Some	_
60-6	10700-10702	of	_
60-7	10703-10706	the	_
60-8	10707-10717	assessment	_
60-9	10718-10729	instruments	_
60-10	10730-10735	named	_
60-11	10736-10741	above	_
60-12	10742-10745	are	_
60-13	10746-10750	part	_
60-14	10751-10753	of	_
60-15	10754-10757	the	_
60-16	10758-10768	BRAINTRAIN	_
60-17	10769-10773	core	_
60-18	10774-10781	outcome	_
60-19	10782-10790	measures	_
60-20	10791-10792	,	_
60-21	10793-10796	i.e	_
60-22	10797-10798	.	_

Text=they are given in all five of the centres involved in the BRAINTRAIN project.
61-1	10799-10803	they	_
61-2	10804-10807	are	_
61-3	10808-10813	given	_
61-4	10814-10816	in	_
61-5	10817-10820	all	_
61-6	10821-10825	five	_
61-7	10826-10828	of	_
61-8	10829-10832	the	_
61-9	10833-10840	centres	_
61-10	10841-10849	involved	_
61-11	10850-10852	in	_
61-12	10853-10856	the	_
61-13	10857-10867	BRAINTRAIN	_
61-14	10868-10875	project	_
61-15	10876-10877	.	_

Text=Some of them (e.g.
62-1	10878-10882	Some	_
62-2	10883-10885	of	_
62-3	10886-10890	them	_
62-4	10891-10892	(	_
62-5	10893-10896	e.g	_
62-6	10897-10898	.	_

Text=those measuring intellectual functioning and thought control) are used mainly to predict who will perform better at NFT and benefit more from it clinically.
63-1	10899-10904	those	_
63-2	10905-10914	measuring	_
63-3	10915-10927	intellectual	_
63-4	10928-10939	functioning	_
63-5	10940-10943	and	_
63-6	10944-10951	thought	_
63-7	10952-10959	control	_
63-8	10960-10961	)	_
63-9	10962-10965	are	_
63-10	10966-10970	used	_
63-11	10971-10977	mainly	_
63-12	10978-10980	to	_
63-13	10981-10988	predict	_
63-14	10989-10992	who	_
63-15	10993-10997	will	_
63-16	10998-11005	perform	_
63-17	11006-11012	better	_
63-18	11013-11015	at	_
63-19	11016-11019	NFT	_
63-20	11020-11023	and	_
63-21	11024-11031	benefit	_
63-22	11032-11036	more	_
63-23	11037-11041	from	_
63-24	11042-11044	it	_
63-25	11045-11055	clinically	_
63-26	11056-11057	.	_

Text=These measures will be used to stratify patients, and they are largely exploratory.
64-1	11058-11063	These	_
64-2	11064-11072	measures	_
64-3	11073-11077	will	_
64-4	11078-11080	be	_
64-5	11081-11085	used	_
64-6	11086-11088	to	_
64-7	11089-11097	stratify	_
64-8	11098-11106	patients	_
64-9	11107-11108	,	_
64-10	11109-11112	and	_
64-11	11113-11117	they	_
64-12	11118-11121	are	_
64-13	11122-11129	largely	_
64-14	11130-11141	exploratory	_
64-15	11142-11143	.	_

Text=Other instruments in this set measure nonspecific clinical factors and comorbidities (e.g.
65-1	11144-11149	Other	_
65-2	11150-11161	instruments	_
65-3	11162-11164	in	_
65-4	11165-11169	this	_
65-5	11170-11173	set	_
65-6	11174-11181	measure	_
65-7	11182-11193	nonspecific	_
65-8	11194-11202	clinical	_
65-9	11203-11210	factors	_
65-10	11211-11214	and	_
65-11	11215-11228	comorbidities	_
65-12	11229-11230	(	_
65-13	11231-11234	e.g	_
65-14	11235-11236	.	_

Text=depression, anxiety) and are included across the different trials to increase the power of secondary outcome measures and to examine nonspecific effects of NFT on mental health (across different diagnoses and research protocols).
66-1	11237-11247	depression	_
66-2	11248-11249	,	_
66-3	11250-11257	anxiety	_
66-4	11258-11259	)	_
66-5	11260-11263	and	_
66-6	11264-11267	are	_
66-7	11268-11276	included	_
66-8	11277-11283	across	_
66-9	11284-11287	the	_
66-10	11288-11297	different	_
66-11	11298-11304	trials	_
66-12	11305-11307	to	_
66-13	11308-11316	increase	_
66-14	11317-11320	the	_
66-15	11321-11326	power	_
66-16	11327-11329	of	_
66-17	11330-11339	secondary	_
66-18	11340-11347	outcome	_
66-19	11348-11356	measures	_
66-20	11357-11360	and	_
66-21	11361-11363	to	_
66-22	11364-11371	examine	_
66-23	11372-11383	nonspecific	_
66-24	11384-11391	effects	_
66-25	11392-11394	of	_
66-26	11395-11398	NFT	_
66-27	11399-11401	on	_
66-28	11402-11408	mental	_
66-29	11409-11415	health	_
66-30	11416-11417	(	_
66-31	11418-11424	across	_
66-32	11425-11434	different	_
66-33	11435-11444	diagnoses	_
66-34	11445-11448	and	_
66-35	11449-11457	research	_
66-36	11458-11467	protocols	_
66-37	11468-11469	)	_
66-38	11470-11471	.	_

Text=Participants are being sent reminders to attend the follow-up sessions.
67-1	11472-11484	Participants	_
67-2	11485-11488	are	_
67-3	11489-11494	being	_
67-4	11495-11499	sent	_
67-5	11500-11509	reminders	_
67-6	11510-11512	to	_
67-7	11513-11519	attend	_
67-8	11520-11523	the	_
67-9	11524-11533	follow-up	_
67-10	11534-11542	sessions	_
67-11	11543-11544	.	_

Text=Whenever possible, outcome data will be collected for all participants whether or not they adhere to the planned intervention.
68-1	11545-11553	Whenever	_
68-2	11554-11562	possible	_
68-3	11563-11564	,	_
68-4	11565-11572	outcome	_
68-5	11573-11577	data	_
68-6	11578-11582	will	_
68-7	11583-11585	be	_
68-8	11586-11595	collected	_
68-9	11596-11599	for	_
68-10	11600-11603	all	_
68-11	11604-11616	participants	_
68-12	11617-11624	whether	_
68-13	11625-11627	or	_
68-14	11628-11631	not	_
68-15	11632-11636	they	_
68-16	11637-11643	adhere	_
68-17	11644-11646	to	_
68-18	11647-11650	the	_
68-19	11651-11658	planned	_
68-20	11659-11671	intervention	_
68-21	11672-11673	.	_

Text=The data will be analysed according to the intention-to-treat principle.
69-1	11674-11677	The	_
69-2	11678-11682	data	_
69-3	11683-11687	will	_
69-4	11688-11690	be	_
69-5	11691-11699	analysed	_
69-6	11700-11709	according	_
69-7	11710-11712	to	_
69-8	11713-11716	the	_
69-9	11717-11735	intention-to-treat	_
69-10	11736-11745	principle	_
69-11	11746-11747	.	_

Text=Intervention During the baseline assessment, participants also perform a computer-based rating task, in which they are presented with a total of 100 pictures showing different categories of alcoholic beverages (wine, beer, spirits, etc.)
70-1	11748-11760	Intervention	_
70-2	11761-11767	During	_
70-3	11768-11771	the	_
70-4	11772-11780	baseline	_
70-5	11781-11791	assessment	_
70-6	11792-11793	,	_
70-7	11794-11806	participants	_
70-8	11807-11811	also	_
70-9	11812-11819	perform	_
70-10	11820-11821	a	_
70-11	11822-11836	computer-based	_
70-12	11837-11843	rating	_
70-13	11844-11848	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
70-14	11849-11850	,	_
70-15	11851-11853	in	_
70-16	11854-11859	which	_
70-17	11860-11864	they	_
70-18	11865-11868	are	_
70-19	11869-11878	presented	_
70-20	11879-11883	with	_
70-21	11884-11885	a	_
70-22	11886-11891	total	_
70-23	11892-11894	of	_
70-24	11895-11898	100	_
70-25	11899-11907	pictures	_
70-26	11908-11915	showing	_
70-27	11916-11925	different	_
70-28	11926-11936	categories	_
70-29	11937-11939	of	_
70-30	11940-11949	alcoholic	_
70-31	11950-11959	beverages	_
70-32	11960-11961	(	_
70-33	11962-11966	wine	_
70-34	11967-11968	,	_
70-35	11969-11973	beer	_
70-36	11974-11975	,	_
70-37	11976-11983	spirits	_
70-38	11984-11985	,	_
70-39	11986-11989	etc	_
70-40	11990-11991	.	_
70-41	11992-11993	)	_

Text=and pub scenes and 100 pictures illustrating alternative, healthy goals (positive personal relationships, health and fitness, employment and career, further education/self-improvement, and personal finances).
71-1	11994-11997	and	_
71-2	11998-12001	pub	_
71-3	12002-12008	scenes	_
71-4	12009-12012	and	_
71-5	12013-12016	100	_
71-6	12017-12025	pictures	_
71-7	12026-12038	illustrating	_
71-8	12039-12050	alternative	_
71-9	12051-12052	,	_
71-10	12053-12060	healthy	_
71-11	12061-12066	goals	_
71-12	12067-12068	(	_
71-13	12069-12077	positive	_
71-14	12078-12086	personal	_
71-15	12087-12100	relationships	_
71-16	12101-12102	,	_
71-17	12103-12109	health	_
71-18	12110-12113	and	_
71-19	12114-12121	fitness	_
71-20	12122-12123	,	_
71-21	12124-12134	employment	_
71-22	12135-12138	and	_
71-23	12139-12145	career	_
71-24	12146-12147	,	_
71-25	12148-12155	further	_
71-26	12156-12182	education/self-improvement	_
71-27	12183-12184	,	_
71-28	12185-12188	and	_
71-29	12189-12197	personal	_
71-30	12198-12206	finances	_
71-31	12207-12208	)	_
71-32	12209-12210	.	_

Text=For each alcohol-related picture, participants are asked to indicate (by using the mouse to move the cursor along a visual analogue scale on the screen) how much this specific picture makes them want a drink of alcohol; response options range from not at all to very strongly.
72-1	12211-12214	For	_
72-2	12215-12219	each	_
72-3	12220-12235	alcohol-related	_
72-4	12236-12243	picture	_
72-5	12244-12245	,	_
72-6	12246-12258	participants	_
72-7	12259-12262	are	_
72-8	12263-12268	asked	_
72-9	12269-12271	to	_
72-10	12272-12280	indicate	_
72-11	12281-12282	(	_
72-12	12283-12285	by	_
72-13	12286-12291	using	_
72-14	12292-12295	the	_
72-15	12296-12301	mouse	_
72-16	12302-12304	to	_
72-17	12305-12309	move	_
72-18	12310-12313	the	_
72-19	12314-12320	cursor	_
72-20	12321-12326	along	_
72-21	12327-12328	a	_
72-22	12329-12335	visual	_
72-23	12336-12344	analogue	_
72-24	12345-12350	scale	_
72-25	12351-12353	on	_
72-26	12354-12357	the	_
72-27	12358-12364	screen	_
72-28	12365-12366	)	_
72-29	12367-12370	how	_
72-30	12371-12375	much	_
72-31	12376-12380	this	_
72-32	12381-12389	specific	_
72-33	12390-12397	picture	_
72-34	12398-12403	makes	_
72-35	12404-12408	them	_
72-36	12409-12413	want	_
72-37	12414-12415	a	_
72-38	12416-12421	drink	_
72-39	12422-12424	of	_
72-40	12425-12432	alcohol	_
72-41	12433-12434	;	_
72-42	12435-12443	response	_
72-43	12444-12451	options	_
72-44	12452-12457	range	_
72-45	12458-12462	from	_
72-46	12463-12466	not	_
72-47	12467-12469	at	_
72-48	12470-12473	all	_
72-49	12474-12476	to	_
72-50	12477-12481	very	_
72-51	12482-12490	strongly	_
72-52	12491-12492	.	_

Text=Using the same response modalities, participants rate each of the pictures related to an alternative goal with regard to how much it reminds them of a positive goal that they are currently pursuing.
73-1	12493-12498	Using	_
73-2	12499-12502	the	_
73-3	12503-12507	same	_
73-4	12508-12516	response	_
73-5	12517-12527	modalities	_
73-6	12528-12529	,	_
73-7	12530-12542	participants	_
73-8	12543-12547	rate	_
73-9	12548-12552	each	_
73-10	12553-12555	of	_
73-11	12556-12559	the	_
73-12	12560-12568	pictures	_
73-13	12569-12576	related	_
73-14	12577-12579	to	_
73-15	12580-12582	an	_
73-16	12583-12594	alternative	_
73-17	12595-12599	goal	_
73-18	12600-12604	with	_
73-19	12605-12611	regard	_
73-20	12612-12614	to	_
73-21	12615-12618	how	_
73-22	12619-12623	much	_
73-23	12624-12626	it	_
73-24	12627-12634	reminds	_
73-25	12635-12639	them	_
73-26	12640-12642	of	_
73-27	12643-12644	a	_
73-28	12645-12653	positive	_
73-29	12654-12658	goal	_
73-30	12659-12663	that	_
73-31	12664-12668	they	_
73-32	12669-12672	are	_
73-33	12673-12682	currently	_
73-34	12683-12691	pursuing	_
73-35	12692-12693	.	_

Text=For each of the subsequent NFT sessions in which alcohol-related pictures are down-regulated or alternative goal-related pictures are up-regulated, the pictures are randomly selected from the 14 pictures in each category that the participant rated most highly.
74-1	12694-12697	For	_
74-2	12698-12702	each	_
74-3	12703-12705	of	_
74-4	12706-12709	the	_
74-5	12710-12720	subsequent	_
74-6	12721-12724	NFT	_
74-7	12725-12733	sessions	_
74-8	12734-12736	in	_
74-9	12737-12742	which	_
74-10	12743-12758	alcohol-related	_
74-11	12759-12767	pictures	_
74-12	12768-12771	are	_
74-13	12772-12786	down-regulated	_
74-14	12787-12789	or	_
74-15	12790-12801	alternative	_
74-16	12802-12814	goal-related	_
74-17	12815-12823	pictures	_
74-18	12824-12827	are	_
74-19	12828-12840	up-regulated	_
74-20	12841-12842	,	_
74-21	12843-12846	the	_
74-22	12847-12855	pictures	_
74-23	12856-12859	are	_
74-24	12860-12868	randomly	_
74-25	12869-12877	selected	_
74-26	12878-12882	from	_
74-27	12883-12886	the	_
74-28	12887-12889	14	_
74-29	12890-12898	pictures	_
74-30	12899-12901	in	_
74-31	12902-12906	each	_
74-32	12907-12915	category	_
74-33	12916-12920	that	_
74-34	12921-12924	the	_
74-35	12925-12936	participant	_
74-36	12937-12942	rated	_
74-37	12943-12947	most	_
74-38	12948-12954	highly	_
74-39	12955-12956	.	_

Text=Thus, the stimulus sets are tailored to each participant ’ s specific drinking preferences and hierarchy of alternative goals.
75-1	12957-12961	Thus	_
75-2	12962-12963	,	_
75-3	12964-12967	the	_
75-4	12968-12976	stimulus	_
75-5	12977-12981	sets	_
75-6	12982-12985	are	_
75-7	12986-12994	tailored	_
75-8	12995-12997	to	_
75-9	12998-13002	each	_
75-10	13003-13014	participant	_
75-11	13015-13016	’	_
75-12	13017-13018	s	_
75-13	13019-13027	specific	_
75-14	13028-13036	drinking	_
75-15	13037-13048	preferences	_
75-16	13049-13052	and	_
75-17	13053-13062	hierarchy	_
75-18	13063-13065	of	_
75-19	13066-13077	alternative	_
75-20	13078-13083	goals	_
75-21	13084-13085	.	_

Text=The NFT involves magnetic resonance imaging (MRI) during which patients lie on a movable bed inside the bore of an MRI scanner.
76-1	13086-13089	The	_
76-2	13090-13093	NFT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
76-3	13094-13102	involves	_
76-4	13103-13111	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-5	13112-13121	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-6	13122-13129	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-7	13130-13131	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-8	13132-13135	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-9	13136-13137	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-10	13138-13144	during	_
76-11	13145-13150	which	_
76-12	13151-13159	patients	_
76-13	13160-13163	lie	_
76-14	13164-13166	on	_
76-15	13167-13168	a	_
76-16	13169-13176	movable	_
76-17	13177-13180	bed	_
76-18	13181-13187	inside	_
76-19	13188-13191	the	_
76-20	13192-13196	bore	_
76-21	13197-13199	of	_
76-22	13200-13202	an	_
76-23	13203-13206	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-24	13207-13214	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
76-25	13215-13216	.	_

Text=Before entering the MRI suite, patients undergo a detailed MRI safety screening (as described earlier), including a determination of potential safety hazards (see exclusion criteria) and the removal of all metal objects, such as keys or jewellery, from their body.
77-1	13217-13223	Before	_
77-2	13224-13232	entering	_
77-3	13233-13236	the	_
77-4	13237-13240	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
77-5	13241-13246	suite	_
77-6	13247-13248	,	_
77-7	13249-13257	patients	_
77-8	13258-13265	undergo	_
77-9	13266-13267	a	_
77-10	13268-13276	detailed	_
77-11	13277-13280	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
77-12	13281-13287	safety	_
77-13	13288-13297	screening	_
77-14	13298-13299	(	_
77-15	13300-13302	as	_
77-16	13303-13312	described	_
77-17	13313-13320	earlier	_
77-18	13321-13322	)	_
77-19	13323-13324	,	_
77-20	13325-13334	including	_
77-21	13335-13336	a	_
77-22	13337-13350	determination	_
77-23	13351-13353	of	_
77-24	13354-13363	potential	_
77-25	13364-13370	safety	_
77-26	13371-13378	hazards	_
77-27	13379-13380	(	_
77-28	13381-13384	see	_
77-29	13385-13394	exclusion	_
77-30	13395-13403	criteria	_
77-31	13404-13405	)	_
77-32	13406-13409	and	_
77-33	13410-13413	the	_
77-34	13414-13421	removal	_
77-35	13422-13424	of	_
77-36	13425-13428	all	_
77-37	13429-13434	metal	_
77-38	13435-13442	objects	_
77-39	13443-13444	,	_
77-40	13445-13449	such	_
77-41	13450-13452	as	_
77-42	13453-13457	keys	_
77-43	13458-13460	or	_
77-44	13461-13470	jewellery	_
77-45	13471-13472	,	_
77-46	13473-13477	from	_
77-47	13478-13483	their	_
77-48	13484-13488	body	_
77-49	13489-13490	.	_

Text=While in the scanner, participants in the experimental group are again exposed to alcohol-related stimuli, such as pictures of alcoholic drinks, and they are trained to regulate their responses in specific brain regions that are activated by the stimuli.
78-1	13491-13496	While	_
78-2	13497-13499	in	_
78-3	13500-13503	the	_
78-4	13504-13511	scanner	_
78-5	13512-13513	,	_
78-6	13514-13526	participants	_
78-7	13527-13529	in	_
78-8	13530-13533	the	_
78-9	13534-13546	experimental	_
78-10	13547-13552	group	_
78-11	13553-13556	are	_
78-12	13557-13562	again	_
78-13	13563-13570	exposed	_
78-14	13571-13573	to	_
78-15	13574-13589	alcohol-related	_
78-16	13590-13597	stimuli	_
78-17	13598-13599	,	_
78-18	13600-13604	such	_
78-19	13605-13607	as	_
78-20	13608-13616	pictures	_
78-21	13617-13619	of	_
78-22	13620-13629	alcoholic	_
78-23	13630-13636	drinks	_
78-24	13637-13638	,	_
78-25	13639-13642	and	_
78-26	13643-13647	they	_
78-27	13648-13651	are	_
78-28	13652-13659	trained	_
78-29	13660-13662	to	_
78-30	13663-13671	regulate	_
78-31	13672-13677	their	_
78-32	13678-13687	responses	_
78-33	13688-13690	in	_
78-34	13691-13699	specific	_
78-35	13700-13705	brain	_
78-36	13706-13713	regions	_
78-37	13714-13718	that	_
78-38	13719-13722	are	_
78-39	13723-13732	activated	_
78-40	13733-13735	by	_
78-41	13736-13739	the	_
78-42	13740-13747	stimuli	_
78-43	13748-13749	.	_

Text=In addition, participants are exposed to pictures showing alternative, socially desirable goals, such as family/relationships or employment.
79-1	13750-13752	In	_
79-2	13753-13761	addition	_
79-3	13762-13763	,	_
79-4	13764-13776	participants	_
79-5	13777-13780	are	_
79-6	13781-13788	exposed	_
79-7	13789-13791	to	_
79-8	13792-13800	pictures	_
79-9	13801-13808	showing	_
79-10	13809-13820	alternative	_
79-11	13821-13822	,	_
79-12	13823-13831	socially	_
79-13	13832-13841	desirable	_
79-14	13842-13847	goals	_
79-15	13848-13849	,	_
79-16	13850-13854	such	_
79-17	13855-13857	as	_
79-18	13858-13878	family/relationships	_
79-19	13879-13881	or	_
79-20	13882-13892	employment	_
79-21	13893-13894	.	_

Text=The rationale for including the two categories of stimuli is that we earlier demonstrated at a neural level that heavy drinking is associated with overvaluation of alcohol and undervaluation of alternative, socially desirable goals.
80-1	13895-13898	The	_
80-2	13899-13908	rationale	_
80-3	13909-13912	for	_
80-4	13913-13922	including	_
80-5	13923-13926	the	_
80-6	13927-13930	two	_
80-7	13931-13941	categories	_
80-8	13942-13944	of	_
80-9	13945-13952	stimuli	_
80-10	13953-13955	is	_
80-11	13956-13960	that	_
80-12	13961-13963	we	_
80-13	13964-13971	earlier	_
80-14	13972-13984	demonstrated	_
80-15	13985-13987	at	_
80-16	13988-13989	a	_
80-17	13990-13996	neural	_
80-18	13997-14002	level	_
80-19	14003-14007	that	_
80-20	14008-14013	heavy	_
80-21	14014-14022	drinking	_
80-22	14023-14025	is	_
80-23	14026-14036	associated	_
80-24	14037-14041	with	_
80-25	14042-14055	overvaluation	_
80-26	14056-14058	of	_
80-27	14059-14066	alcohol	_
80-28	14067-14070	and	_
80-29	14071-14085	undervaluation	_
80-30	14086-14088	of	_
80-31	14089-14100	alternative	_
80-32	14101-14102	,	_
80-33	14103-14111	socially	_
80-34	14112-14121	desirable	_
80-35	14122-14127	goals	_
80-36	14128-14129	.	_

Text=Moreover, consistent with motivational theory, it has been shown that problem drinkers ’ success in reducing their drinking is associated with the degree to which they have other satisfying alternative goals to pursue and enjoy.
81-1	14130-14138	Moreover	_
81-2	14139-14140	,	_
81-3	14141-14151	consistent	_
81-4	14152-14156	with	_
81-5	14157-14169	motivational	_
81-6	14170-14176	theory	_
81-7	14177-14178	,	_
81-8	14179-14181	it	_
81-9	14182-14185	has	_
81-10	14186-14190	been	_
81-11	14191-14196	shown	_
81-12	14197-14201	that	_
81-13	14202-14209	problem	_
81-14	14210-14218	drinkers	_
81-15	14219-14220	’	_
81-16	14221-14228	success	_
81-17	14229-14231	in	_
81-18	14232-14240	reducing	_
81-19	14241-14246	their	_
81-20	14247-14255	drinking	_
81-21	14256-14258	is	_
81-22	14259-14269	associated	_
81-23	14270-14274	with	_
81-24	14275-14278	the	_
81-25	14279-14285	degree	_
81-26	14286-14288	to	_
81-27	14289-14294	which	_
81-28	14295-14299	they	_
81-29	14300-14304	have	_
81-30	14305-14310	other	_
81-31	14311-14321	satisfying	_
81-32	14322-14333	alternative	_
81-33	14334-14339	goals	_
81-34	14340-14342	to	_
81-35	14343-14349	pursue	_
81-36	14350-14353	and	_
81-37	14354-14359	enjoy	_
81-38	14360-14361	.	_

Text=The size of the images that participants see corresponds to the level of activation.
82-1	14362-14365	The	_
82-2	14366-14370	size	_
82-3	14371-14373	of	_
82-4	14374-14377	the	_
82-5	14378-14384	images	_
82-6	14385-14389	that	_
82-7	14390-14402	participants	_
82-8	14403-14406	see	_
82-9	14407-14418	corresponds	_
82-10	14419-14421	to	_
82-11	14422-14425	the	_
82-12	14426-14431	level	_
82-13	14432-14434	of	_
82-14	14435-14445	activation	_
82-15	14446-14447	.	_

Text=They are told to use any kind of mental strategy at their disposal (e.g.
83-1	14448-14452	They	_
83-2	14453-14456	are	_
83-3	14457-14461	told	_
83-4	14462-14464	to	_
83-5	14465-14468	use	_
83-6	14469-14472	any	_
83-7	14473-14477	kind	_
83-8	14478-14480	of	_
83-9	14481-14487	mental	_
83-10	14488-14496	strategy	_
83-11	14497-14499	at	_
83-12	14500-14505	their	_
83-13	14506-14514	disposal	_
83-14	14515-14516	(	_
83-15	14517-14520	e.g	_
83-16	14521-14522	.	_

Text=thinking about the negative consequences of drinking) that helps to reduce size of the image (in the case of alcohol pictures) or increase size of the image and thereby the degree of brain activation (in the case of healthy, goal-related pictures).
84-1	14523-14531	thinking	_
84-2	14532-14537	about	_
84-3	14538-14541	the	_
84-4	14542-14550	negative	_
84-5	14551-14563	consequences	_
84-6	14564-14566	of	_
84-7	14567-14575	drinking	_
84-8	14576-14577	)	_
84-9	14578-14582	that	_
84-10	14583-14588	helps	_
84-11	14589-14591	to	_
84-12	14592-14598	reduce	_
84-13	14599-14603	size	_
84-14	14604-14606	of	_
84-15	14607-14610	the	_
84-16	14611-14616	image	_
84-17	14617-14618	(	_
84-18	14619-14621	in	_
84-19	14622-14625	the	_
84-20	14626-14630	case	_
84-21	14631-14633	of	_
84-22	14634-14641	alcohol	_
84-23	14642-14650	pictures	_
84-24	14651-14652	)	_
84-25	14653-14655	or	_
84-26	14656-14664	increase	_
84-27	14665-14669	size	_
84-28	14670-14672	of	_
84-29	14673-14676	the	_
84-30	14677-14682	image	_
84-31	14683-14686	and	_
84-32	14687-14694	thereby	_
84-33	14695-14698	the	_
84-34	14699-14705	degree	_
84-35	14706-14708	of	_
84-36	14709-14714	brain	_
84-37	14715-14725	activation	_
84-38	14726-14727	(	_
84-39	14728-14730	in	_
84-40	14731-14734	the	_
84-41	14735-14739	case	_
84-42	14740-14742	of	_
84-43	14743-14750	healthy	_
84-44	14751-14752	,	_
84-45	14753-14765	goal-related	_
84-46	14766-14774	pictures	_
84-47	14775-14776	)	_
84-48	14777-14778	.	_

Text=Experimental participants have six NFT training sessions spread across 4 months, and they are also asked to practice at home the mental strategies they used in the MRI scanner.
85-1	14779-14791	Experimental	_
85-2	14792-14804	participants	_
85-3	14805-14809	have	_
85-4	14810-14813	six	_
85-5	14814-14817	NFT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
85-6	14818-14826	training	_
85-7	14827-14835	sessions	_
85-8	14836-14842	spread	_
85-9	14843-14849	across	_
85-10	14850-14851	4	_
85-11	14852-14858	months	_
85-12	14859-14860	,	_
85-13	14861-14864	and	_
85-14	14865-14869	they	_
85-15	14870-14873	are	_
85-16	14874-14878	also	_
85-17	14879-14884	asked	_
85-18	14885-14887	to	_
85-19	14888-14896	practice	_
85-20	14897-14899	at	_
85-21	14900-14904	home	_
85-22	14905-14908	the	_
85-23	14909-14915	mental	_
85-24	14916-14926	strategies	_
85-25	14927-14931	they	_
85-26	14932-14936	used	_
85-27	14937-14939	in	_
85-28	14940-14943	the	_
85-29	14944-14947	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
85-30	14948-14955	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
85-31	14956-14957	.	_

Text=They also (1) rate their urges to drink before, during, and after each training session, and (2) complete questionnaires and other tests to measure their alcohol consumption and other relevant aspects of their behaviour.
86-1	14958-14962	They	_
86-2	14963-14967	also	_
86-3	14968-14969	(	_
86-4	14970-14971	1	_
86-5	14972-14973	)	_
86-6	14974-14978	rate	_
86-7	14979-14984	their	_
86-8	14985-14990	urges	_
86-9	14991-14993	to	_
86-10	14994-14999	drink	_
86-11	15000-15006	before	_
86-12	15007-15008	,	_
86-13	15009-15015	during	_
86-14	15016-15017	,	_
86-15	15018-15021	and	_
86-16	15022-15027	after	_
86-17	15028-15032	each	_
86-18	15033-15041	training	_
86-19	15042-15049	session	_
86-20	15050-15051	,	_
86-21	15052-15055	and	_
86-22	15056-15057	(	_
86-23	15058-15059	2	_
86-24	15060-15061	)	_
86-25	15062-15070	complete	_
86-26	15071-15085	questionnaires	_
86-27	15086-15089	and	_
86-28	15090-15095	other	_
86-29	15096-15101	tests	_
86-30	15102-15104	to	_
86-31	15105-15112	measure	_
86-32	15113-15118	their	_
86-33	15119-15126	alcohol	_
86-34	15127-15138	consumption	_
86-35	15139-15142	and	_
86-36	15143-15148	other	_
86-37	15149-15157	relevant	_
86-38	15158-15165	aspects	_
86-39	15166-15168	of	_
86-40	15169-15174	their	_
86-41	15175-15184	behaviour	_
86-42	15185-15186	.	_

Text=Control participants complete the same measures that are timed to coincide with their administration to the experimental group.
87-1	15187-15194	Control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
87-2	15195-15207	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
87-3	15208-15216	complete	_
87-4	15217-15220	the	_
87-5	15221-15225	same	_
87-6	15226-15234	measures	_
87-7	15235-15239	that	_
87-8	15240-15243	are	_
87-9	15244-15249	timed	_
87-10	15250-15252	to	_
87-11	15253-15261	coincide	_
87-12	15262-15266	with	_
87-13	15267-15272	their	_
87-14	15273-15287	administration	_
87-15	15288-15290	to	_
87-16	15291-15294	the	_
87-17	15295-15307	experimental	_
87-18	15308-15313	group	_
87-19	15314-15315	.	_

Text=The primary outcome measures are obtained 4 months after the baseline assessment.
88-1	15316-15319	The	_
88-2	15320-15327	primary	_
88-3	15328-15335	outcome	_
88-4	15336-15344	measures	_
88-5	15345-15348	are	_
88-6	15349-15357	obtained	_
88-7	15358-15359	4	_
88-8	15360-15366	months	_
88-9	15367-15372	after	_
88-10	15373-15376	the	_
88-11	15377-15385	baseline	_
88-12	15386-15396	assessment	_
88-13	15397-15398	.	_

Text=Eight and 12 months after baseline assessment both groups complete a follow-up assessment battery.
89-1	15399-15404	Eight	_
89-2	15405-15408	and	_
89-3	15409-15411	12	_
89-4	15412-15418	months	_
89-5	15419-15424	after	_
89-6	15425-15433	baseline	_
89-7	15434-15444	assessment	_
89-8	15445-15449	both	_
89-9	15450-15456	groups	_
89-10	15457-15465	complete	_
89-11	15466-15467	a	_
89-12	15468-15477	follow-up	_
89-13	15478-15488	assessment	_
89-14	15489-15496	battery	_
89-15	15497-15498	.	_

Text=For the duration of the scanning session, several additional physiological parameters are measured, including heart rate via a finger pulse sensor and respiratory rate via a belt affixed to the participant ’ s chest.
90-1	15499-15502	For	_
90-2	15503-15506	the	_
90-3	15507-15515	duration	_
90-4	15516-15518	of	_
90-5	15519-15522	the	_
90-6	15523-15531	scanning	_
90-7	15532-15539	session	_
90-8	15540-15541	,	_
90-9	15542-15549	several	_
90-10	15550-15560	additional	_
90-11	15561-15574	physiological	_
90-12	15575-15585	parameters	_
90-13	15586-15589	are	_
90-14	15590-15598	measured	_
90-15	15599-15600	,	_
90-16	15601-15610	including	_
90-17	15611-15616	heart	_
90-18	15617-15621	rate	_
90-19	15622-15625	via	_
90-20	15626-15627	a	_
90-21	15628-15634	finger	_
90-22	15635-15640	pulse	_
90-23	15641-15647	sensor	_
90-24	15648-15651	and	_
90-25	15652-15663	respiratory	_
90-26	15664-15668	rate	_
90-27	15669-15672	via	_
90-28	15673-15674	a	_
90-29	15675-15679	belt	_
90-30	15680-15687	affixed	_
90-31	15688-15690	to	_
90-32	15691-15694	the	_
90-33	15695-15706	participant	_
90-34	15707-15708	’	_
90-35	15709-15710	s	_
90-36	15711-15716	chest	_
90-37	15717-15718	.	_

Text=Participants are able to see outside the scanner during the scan, and radiographers are able to see and monitor participants from the control room.
91-1	15719-15731	Participants	_
91-2	15732-15735	are	_
91-3	15736-15740	able	_
91-4	15741-15743	to	_
91-5	15744-15747	see	_
91-6	15748-15755	outside	_
91-7	15756-15759	the	_
91-8	15760-15767	scanner	_
91-9	15768-15774	during	_
91-10	15775-15778	the	_
91-11	15779-15783	scan	_
91-12	15784-15785	,	_
91-13	15786-15789	and	_
91-14	15790-15803	radiographers	_
91-15	15804-15807	are	_
91-16	15808-15812	able	_
91-17	15813-15815	to	_
91-18	15816-15819	see	_
91-19	15820-15823	and	_
91-20	15824-15831	monitor	_
91-21	15832-15844	participants	_
91-22	15845-15849	from	_
91-23	15850-15853	the	_
91-24	15854-15861	control	_
91-25	15862-15866	room	_
91-26	15867-15868	.	_

Text=Participants are given a call button to press if they need to communicate with someone outside the scanner.
92-1	15869-15881	Participants	_
92-2	15882-15885	are	_
92-3	15886-15891	given	_
92-4	15892-15893	a	_
92-5	15894-15898	call	_
92-6	15899-15905	button	_
92-7	15906-15908	to	_
92-8	15909-15914	press	_
92-9	15915-15917	if	_
92-10	15918-15922	they	_
92-11	15923-15927	need	_
92-12	15928-15930	to	_
92-13	15931-15942	communicate	_
92-14	15943-15947	with	_
92-15	15948-15955	someone	_
92-16	15956-15963	outside	_
92-17	15964-15967	the	_
92-18	15968-15975	scanner	_
92-19	15976-15977	.	_

Text=The scan can be stopped at any time at a participant ’ s request (e.g.
93-1	15978-15981	The	_
93-2	15982-15986	scan	_
93-3	15987-15990	can	_
93-4	15991-15993	be	_
93-5	15994-16001	stopped	_
93-6	16002-16004	at	_
93-7	16005-16008	any	_
93-8	16009-16013	time	_
93-9	16014-16016	at	_
93-10	16017-16018	a	_
93-11	16019-16030	participant	_
93-12	16031-16032	’	_
93-13	16033-16034	s	_
93-14	16035-16042	request	_
93-15	16043-16044	(	_
93-16	16045-16048	e.g	_
93-17	16049-16050	.	_

Text=if he or she feels uncomfortable) or if the radiographer becomes concerned about a participant ’ s wellbeing.
94-1	16051-16053	if	_
94-2	16054-16056	he	_
94-3	16057-16059	or	_
94-4	16060-16063	she	_
94-5	16064-16069	feels	_
94-6	16070-16083	uncomfortable	_
94-7	16084-16085	)	_
94-8	16086-16088	or	_
94-9	16089-16091	if	_
94-10	16092-16095	the	_
94-11	16096-16108	radiographer	_
94-12	16109-16116	becomes	_
94-13	16117-16126	concerned	_
94-14	16127-16132	about	_
94-15	16133-16134	a	_
94-16	16135-16146	participant	_
94-17	16147-16148	’	_
94-18	16149-16150	s	_
94-19	16151-16160	wellbeing	_
94-20	16161-16162	.	_

Text=Imaging data are acquired using the 3T General Electric HDx or Siemens Prisma scanners at the Cardiff University Brain Research Imaging Centre (CUBRIC) and standard parameters for functional and structural brain imaging.
95-1	16163-16170	Imaging	_
95-2	16171-16175	data	_
95-3	16176-16179	are	_
95-4	16180-16188	acquired	_
95-5	16189-16194	using	_
95-6	16195-16198	the	_
95-7	16199-16201	3T	_
95-8	16202-16209	General	_
95-9	16210-16218	Electric	_
95-10	16219-16222	HDx	_
95-11	16223-16225	or	_
95-12	16226-16233	Siemens	_
95-13	16234-16240	Prisma	_
95-14	16241-16249	scanners	_
95-15	16250-16252	at	_
95-16	16253-16256	the	_
95-17	16257-16264	Cardiff	_
95-18	16265-16275	University	_
95-19	16276-16281	Brain	_
95-20	16282-16290	Research	_
95-21	16291-16298	Imaging	_
95-22	16299-16305	Centre	_
95-23	16306-16307	(	_
95-24	16308-16314	CUBRIC	_
95-25	16315-16316	)	_
95-26	16317-16320	and	_
95-27	16321-16329	standard	_
95-28	16330-16340	parameters	_
95-29	16341-16344	for	_
95-30	16345-16355	functional	_
95-31	16356-16359	and	_
95-32	16360-16370	structural	_
95-33	16371-16376	brain	_
95-34	16377-16384	imaging	_
95-35	16385-16386	.	_

Text=Blood oxygenation level-dependent (BOLD) signals during localiser and neurofeedback runs (see description below) are measured with a T2 * -weighted gradient echo planar imaging (EPI) sequence that is synchronised to the onset of the stimulus presentation.
96-1	16387-16392	Blood	_
96-2	16393-16404	oxygenation	_
96-3	16405-16420	level-dependent	_
96-4	16421-16422	(	http://maven.renci.org/NeuroBridge/neurobridge#BreathHoldTask
96-5	16423-16427	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#BreathHoldTask
96-6	16428-16429	)	_
96-7	16430-16437	signals	_
96-8	16438-16444	during	_
96-9	16445-16454	localiser	_
96-10	16455-16458	and	_
96-11	16459-16472	neurofeedback	_
96-12	16473-16477	runs	_
96-13	16478-16479	(	_
96-14	16480-16483	see	_
96-15	16484-16495	description	_
96-16	16496-16501	below	_
96-17	16502-16503	)	_
96-18	16504-16507	are	_
96-19	16508-16516	measured	_
96-20	16517-16521	with	_
96-21	16522-16523	a	_
96-22	16524-16526	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-23	16527-16528	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-24	16529-16538	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-25	16539-16547	gradient	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-26	16548-16552	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-27	16553-16559	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-28	16560-16567	imaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-29	16568-16569	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-30	16570-16573	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-31	16574-16575	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-32	16576-16584	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
96-33	16585-16589	that	_
96-34	16590-16592	is	_
96-35	16593-16605	synchronised	_
96-36	16606-16608	to	_
96-37	16609-16612	the	_
96-38	16613-16618	onset	_
96-39	16619-16621	of	_
96-40	16622-16625	the	_
96-41	16626-16634	stimulus	_
96-42	16635-16647	presentation	_
96-43	16648-16649	.	_

Text=Each functional EPI volume contains 24 slices of 2.5-mm thickness, with 0.5-mm inter-slice spacing (in-plane resolution = 3 mm, matrix size = 64 × 64, FoV (field of view) = 192 mm, TR (repetition time) = 1500 ms, TE (echo time) = 30 ms, flip angle = 80°, orientation = transversal).
97-1	16650-16654	Each	_
97-2	16655-16665	functional	_
97-3	16666-16669	EPI	_
97-4	16670-16676	volume	_
97-5	16677-16685	contains	_
97-6	16686-16688	24	_
97-7	16689-16695	slices	_
97-8	16696-16698	of	_
97-9	16699-16705	2.5-mm	_
97-10	16706-16715	thickness	_
97-11	16716-16717	,	_
97-12	16718-16722	with	_
97-13	16723-16729	0.5-mm	_
97-14	16730-16741	inter-slice	_
97-15	16742-16749	spacing	_
97-16	16750-16751	(	_
97-17	16752-16760	in-plane	_
97-18	16761-16771	resolution	_
97-19	16772-16773	=	_
97-20	16774-16775	3	_
97-21	16776-16778	mm	_
97-22	16779-16780	,	_
97-23	16781-16787	matrix	_
97-24	16788-16792	size	_
97-25	16793-16794	=	_
97-26	16795-16797	64	_
97-27	16798-16799	×	_
97-28	16800-16802	64	_
97-29	16803-16804	,	_
97-30	16805-16808	FoV	_
97-31	16809-16810	(	_
97-32	16811-16816	field	_
97-33	16817-16819	of	_
97-34	16820-16824	view	_
97-35	16825-16826	)	_
97-36	16827-16828	=	_
97-37	16829-16832	192	_
97-38	16833-16835	mm	_
97-39	16836-16837	,	_
97-40	16838-16840	TR	_
97-41	16841-16842	(	_
97-42	16843-16853	repetition	_
97-43	16854-16858	time	_
97-44	16859-16860	)	_
97-45	16861-16862	=	_
97-46	16863-16867	1500	_
97-47	16868-16870	ms	_
97-48	16871-16872	,	_
97-49	16873-16875	TE	_
97-50	16876-16877	(	_
97-51	16878-16882	echo	_
97-52	16883-16887	time	_
97-53	16888-16889	)	_
97-54	16890-16891	=	_
97-55	16892-16894	30	_
97-56	16895-16897	ms	_
97-57	16898-16899	,	_
97-58	16900-16904	flip	_
97-59	16905-16910	angle	_
97-60	16911-16912	=	_
97-61	16913-16916	80°	_
97-62	16917-16918	,	_
97-63	16919-16930	orientation	_
97-64	16931-16932	=	_
97-65	16933-16944	transversal	_
97-66	16945-16946	)	_
97-67	16947-16948	.	_

Text=High-resolution structural images are acquired before the first functional scan using a fast spoiled gradient echo sequence (FSPGR) with 172 contiguous sagittal slices of 1-mm thickness (voxel size: 1 × 1 × 1 mm, TR = 7.9 s, TE = 3.0 ms, flip angle = 20°, FoV = 256 × 256 × 172 mm).
98-1	16949-16964	High-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
98-2	16965-16975	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
98-3	16976-16982	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
98-4	16983-16986	are	_
98-5	16987-16995	acquired	_
98-6	16996-17002	before	_
98-7	17003-17006	the	_
98-8	17007-17012	first	_
98-9	17013-17023	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
98-10	17024-17028	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
98-11	17029-17034	using	_
98-12	17035-17036	a	_
98-13	17037-17041	fast	_
98-14	17042-17049	spoiled	_
98-15	17050-17058	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-16	17059-17063	echo	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-17	17064-17072	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-18	17073-17074	(	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-19	17075-17080	FSPGR	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-20	17081-17082	)	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
98-21	17083-17087	with	_
98-22	17088-17091	172	_
98-23	17092-17102	contiguous	_
98-24	17103-17111	sagittal	_
98-25	17112-17118	slices	_
98-26	17119-17121	of	_
98-27	17122-17126	1-mm	_
98-28	17127-17136	thickness	_
98-29	17137-17138	(	_
98-30	17139-17144	voxel	_
98-31	17145-17149	size	_
98-32	17150-17151	:	_
98-33	17152-17153	1	_
98-34	17154-17155	×	_
98-35	17156-17157	1	_
98-36	17158-17159	×	_
98-37	17160-17161	1	_
98-38	17162-17164	mm	_
98-39	17165-17166	,	_
98-40	17167-17169	TR	_
98-41	17170-17171	=	_
98-42	17172-17175	7.9	_
98-43	17176-17177	s	_
98-44	17178-17179	,	_
98-45	17180-17182	TE	_
98-46	17183-17184	=	_
98-47	17185-17188	3.0	_
98-48	17189-17191	ms	_
98-49	17192-17193	,	_
98-50	17194-17198	flip	_
98-51	17199-17204	angle	_
98-52	17205-17206	=	_
98-53	17207-17210	20°	_
98-54	17211-17212	,	_
98-55	17213-17216	FoV	_
98-56	17217-17218	=	_
98-57	17219-17222	256	_
98-58	17223-17224	×	_
98-59	17225-17228	256	_
98-60	17229-17230	×	_
98-61	17231-17234	172	_
98-62	17235-17237	mm	_
98-63	17238-17239	)	_
98-64	17240-17241	.	_

Text=The basic neurofeedback setup being used in the trial is illustrated in Fig.
99-1	17242-17245	The	_
99-2	17246-17251	basic	_
99-3	17252-17265	neurofeedback	_
99-4	17266-17271	setup	_
99-5	17272-17277	being	_
99-6	17278-17282	used	_
99-7	17283-17285	in	_
99-8	17286-17289	the	_
99-9	17290-17295	trial	_
99-10	17296-17298	is	_
99-11	17299-17310	illustrated	_
99-12	17311-17313	in	_
99-13	17314-17317	Fig	_
99-14	17318-17319	.	_

Text=2.
100-1	17320-17321	2	_
100-2	17322-17323	.	_

Text=Patients are asked to lie still throughout the scanning sessions; they are in the scanner for no longer than 90 min.
101-1	17324-17332	Patients	_
101-2	17333-17336	are	_
101-3	17337-17342	asked	_
101-4	17343-17345	to	_
101-5	17346-17349	lie	_
101-6	17350-17355	still	_
101-7	17356-17366	throughout	_
101-8	17367-17370	the	_
101-9	17371-17379	scanning	_
101-10	17380-17388	sessions	_
101-11	17389-17390	;	_
101-12	17391-17395	they	_
101-13	17396-17399	are	_
101-14	17400-17402	in	_
101-15	17403-17406	the	_
101-16	17407-17414	scanner	_
101-17	17415-17418	for	_
101-18	17419-17421	no	_
101-19	17422-17428	longer	_
101-20	17429-17433	than	_
101-21	17434-17436	90	_
101-22	17437-17440	min	_
101-23	17441-17442	.	_

Text=During the scan, patients are exposed to pictorial stimuli (depicting either alcoholic drinks or alternative goals), which are projected onto a screen behind the scanner and viewed through a mirror attached on the MRI head coil.
102-1	17443-17449	During	_
102-2	17450-17453	the	_
102-3	17454-17458	scan	_
102-4	17459-17460	,	_
102-5	17461-17469	patients	_
102-6	17470-17473	are	_
102-7	17474-17481	exposed	_
102-8	17482-17484	to	_
102-9	17485-17494	pictorial	_
102-10	17495-17502	stimuli	_
102-11	17503-17504	(	_
102-12	17505-17514	depicting	_
102-13	17515-17521	either	_
102-14	17522-17531	alcoholic	_
102-15	17532-17538	drinks	_
102-16	17539-17541	or	_
102-17	17542-17553	alternative	_
102-18	17554-17559	goals	_
102-19	17560-17561	)	_
102-20	17562-17563	,	_
102-21	17564-17569	which	_
102-22	17570-17573	are	_
102-23	17574-17583	projected	_
102-24	17584-17588	onto	_
102-25	17589-17590	a	_
102-26	17591-17597	screen	_
102-27	17598-17604	behind	_
102-28	17605-17608	the	_
102-29	17609-17616	scanner	_
102-30	17617-17620	and	_
102-31	17621-17627	viewed	_
102-32	17628-17635	through	_
102-33	17636-17637	a	_
102-34	17638-17644	mirror	_
102-35	17645-17653	attached	_
102-36	17654-17656	on	_
102-37	17657-17660	the	_
102-38	17661-17664	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
102-39	17665-17669	head	_
102-40	17670-17674	coil	_
102-41	17675-17676	.	_

Text=Functional MRI (fMRI) data are acquired in short blocks (runs) having a duration of 7.5 min.
103-1	17677-17687	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
103-2	17688-17691	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
103-3	17692-17693	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
103-4	17694-17698	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
103-5	17699-17700	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
103-6	17701-17705	data	_
103-7	17706-17709	are	_
103-8	17710-17718	acquired	_
103-9	17719-17721	in	_
103-10	17722-17727	short	_
103-11	17728-17734	blocks	_
103-12	17735-17736	(	_
103-13	17737-17741	runs	_
103-14	17742-17743	)	_
103-15	17744-17750	having	_
103-16	17751-17752	a	_
103-17	17753-17761	duration	_
103-18	17762-17764	of	_
103-19	17765-17768	7.5	_
103-20	17769-17772	min	_
103-21	17773-17774	.	_

Text=The first run serves as the localiser procedure in which we present in alternating blocks of 30-s alcohol-related pictures or goal-related pictures and neutral pictures (household objects).
104-1	17775-17778	The	_
104-2	17779-17784	first	_
104-3	17785-17788	run	_
104-4	17789-17795	serves	_
104-5	17796-17798	as	_
104-6	17799-17802	the	_
104-7	17803-17812	localiser	_
104-8	17813-17822	procedure	_
104-9	17823-17825	in	_
104-10	17826-17831	which	_
104-11	17832-17834	we	_
104-12	17835-17842	present	_
104-13	17843-17845	in	_
104-14	17846-17857	alternating	_
104-15	17858-17864	blocks	_
104-16	17865-17867	of	_
104-17	17868-17872	30-s	_
104-18	17873-17888	alcohol-related	_
104-19	17889-17897	pictures	_
104-20	17898-17900	or	_
104-21	17901-17913	goal-related	_
104-22	17914-17922	pictures	_
104-23	17923-17926	and	_
104-24	17927-17934	neutral	_
104-25	17935-17943	pictures	_
104-26	17944-17945	(	_
104-27	17946-17955	household	_
104-28	17956-17963	objects	_
104-29	17964-17965	)	_
104-30	17966-17967	.	_

Text=Each block contains 15 different pictures of the same category (2 s per picture) and is followed by a fixation (rest) period.
105-1	17968-17972	Each	_
105-2	17973-17978	block	_
105-3	17979-17987	contains	_
105-4	17988-17990	15	_
105-5	17991-18000	different	_
105-6	18001-18009	pictures	_
105-7	18010-18012	of	_
105-8	18013-18016	the	_
105-9	18017-18021	same	_
105-10	18022-18030	category	_
105-11	18031-18032	(	_
105-12	18033-18034	2	_
105-13	18035-18036	s	_
105-14	18037-18040	per	_
105-15	18041-18048	picture	_
105-16	18049-18050	)	_
105-17	18051-18054	and	_
105-18	18055-18057	is	_
105-19	18058-18066	followed	_
105-20	18067-18069	by	_
105-21	18070-18071	a	_
105-22	18072-18080	fixation	_
105-23	18081-18082	(	_
105-24	18083-18087	rest	_
105-25	18088-18089	)	_
105-26	18090-18096	period	_
105-27	18097-18098	.	_

Text=Participants are instructed to attentively watch the pictures without any cognitive/emotional regulation of the responses that are elicited by these pictures.
106-1	18099-18111	Participants	_
106-2	18112-18115	are	_
106-3	18116-18126	instructed	_
106-4	18127-18129	to	_
106-5	18130-18141	attentively	_
106-6	18142-18147	watch	_
106-7	18148-18151	the	_
106-8	18152-18160	pictures	_
106-9	18161-18168	without	_
106-10	18169-18172	any	_
106-11	18173-18192	cognitive/emotional	_
106-12	18193-18203	regulation	_
106-13	18204-18206	of	_
106-14	18207-18210	the	_
106-15	18211-18220	responses	_
106-16	18221-18225	that	_
106-17	18226-18229	are	_
106-18	18230-18238	elicited	_
106-19	18239-18241	by	_
106-20	18242-18247	these	_
106-21	18248-18256	pictures	_
106-22	18257-18258	.	_

Text=Based on real-time preprocessing and statistical analysis of the BOLD signal recorded during the localiser, a specific target brain area (either alcohol- or goal-related) is individually selected for each participant in each session.
107-1	18259-18264	Based	_
107-2	18265-18267	on	_
107-3	18268-18277	real-time	_
107-4	18278-18291	preprocessing	_
107-5	18292-18295	and	_
107-6	18296-18307	statistical	_
107-7	18308-18316	analysis	_
107-8	18317-18319	of	_
107-9	18320-18323	the	_
107-10	18324-18328	BOLD	_
107-11	18329-18335	signal	_
107-12	18336-18344	recorded	_
107-13	18345-18351	during	_
107-14	18352-18355	the	_
107-15	18356-18365	localiser	_
107-16	18366-18367	,	_
107-17	18368-18369	a	_
107-18	18370-18378	specific	_
107-19	18379-18385	target	_
107-20	18386-18391	brain	_
107-21	18392-18396	area	_
107-22	18397-18398	(	_
107-23	18399-18405	either	_
107-24	18406-18414	alcohol-	_
107-25	18415-18417	or	_
107-26	18418-18430	goal-related	_
107-27	18431-18432	)	_
107-28	18433-18435	is	_
107-29	18436-18448	individually	_
107-30	18449-18457	selected	_
107-31	18458-18461	for	_
107-32	18462-18466	each	_
107-33	18467-18478	participant	_
107-34	18479-18481	in	_
107-35	18482-18486	each	_
107-36	18487-18494	session	_
107-37	18495-18496	.	_

Text=Statistically significant regions of interest (ROIs) are selected using a t-contrast of alcohol/goal-related versus neutral images, and a variable t-threshold to ensure that a robust cluster is activated in a functionally relevant area (minimum of four connected voxels).
108-1	18497-18510	Statistically	_
108-2	18511-18522	significant	_
108-3	18523-18530	regions	_
108-4	18531-18533	of	_
108-5	18534-18542	interest	_
108-6	18543-18544	(	_
108-7	18545-18549	ROIs	_
108-8	18550-18551	)	_
108-9	18552-18555	are	_
108-10	18556-18564	selected	_
108-11	18565-18570	using	_
108-12	18571-18572	a	_
108-13	18573-18583	t-contrast	_
108-14	18584-18586	of	_
108-15	18587-18607	alcohol/goal-related	_
108-16	18608-18614	versus	_
108-17	18615-18622	neutral	_
108-18	18623-18629	images	_
108-19	18630-18631	,	_
108-20	18632-18635	and	_
108-21	18636-18637	a	_
108-22	18638-18646	variable	_
108-23	18647-18658	t-threshold	_
108-24	18659-18661	to	_
108-25	18662-18668	ensure	_
108-26	18669-18673	that	_
108-27	18674-18675	a	_
108-28	18676-18682	robust	_
108-29	18683-18690	cluster	_
108-30	18691-18693	is	_
108-31	18694-18703	activated	_
108-32	18704-18706	in	_
108-33	18707-18708	a	_
108-34	18709-18721	functionally	_
108-35	18722-18730	relevant	_
108-36	18731-18735	area	_
108-37	18736-18737	(	_
108-38	18738-18745	minimum	_
108-39	18746-18748	of	_
108-40	18749-18753	four	_
108-41	18754-18763	connected	_
108-42	18764-18770	voxels	_
108-43	18771-18772	)	_
108-44	18773-18774	.	_

Text=The next four runs consist of two NFT runs, during which the participant attempts to self-regulate activation in the target area, and two mirror (M) runs in the order NFT-M-NFT-M. During mirror runs, the previous feedback-modulated stimulus is presented, but participants are instructed to passively view it and not attempt to regulate their response.
109-1	18775-18778	The	_
109-2	18779-18783	next	_
109-3	18784-18788	four	_
109-4	18789-18793	runs	_
109-5	18794-18801	consist	_
109-6	18802-18804	of	_
109-7	18805-18808	two	_
109-8	18809-18812	NFT	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
109-9	18813-18817	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
109-10	18818-18819	,	_
109-11	18820-18826	during	_
109-12	18827-18832	which	_
109-13	18833-18836	the	_
109-14	18837-18848	participant	_
109-15	18849-18857	attempts	_
109-16	18858-18860	to	_
109-17	18861-18874	self-regulate	_
109-18	18875-18885	activation	_
109-19	18886-18888	in	_
109-20	18889-18892	the	_
109-21	18893-18899	target	_
109-22	18900-18904	area	_
109-23	18905-18906	,	_
109-24	18907-18910	and	_
109-25	18911-18914	two	_
109-26	18915-18921	mirror	_
109-27	18922-18923	(	_
109-28	18924-18925	M	_
109-29	18926-18927	)	_
109-30	18928-18932	runs	_
109-31	18933-18935	in	_
109-32	18936-18939	the	_
109-33	18940-18945	order	_
109-34	18946-18958	NFT-M-NFT-M.	_
109-35	18959-18965	During	_
109-36	18966-18972	mirror	_
109-37	18973-18977	runs	_
109-38	18978-18979	,	_
109-39	18980-18983	the	_
109-40	18984-18992	previous	_
109-41	18993-19011	feedback-modulated	_
109-42	19012-19020	stimulus	_
109-43	19021-19023	is	_
109-44	19024-19033	presented	_
109-45	19034-19035	,	_
109-46	19036-19039	but	_
109-47	19040-19052	participants	_
109-48	19053-19056	are	_
109-49	19057-19067	instructed	_
109-50	19068-19070	to	_
109-51	19071-19080	passively	_
109-52	19081-19085	view	_
109-53	19086-19088	it	_
109-54	19089-19092	and	_
109-55	19093-19096	not	_
109-56	19097-19104	attempt	_
109-57	19105-19107	to	_
109-58	19108-19116	regulate	_
109-59	19117-19122	their	_
109-60	19123-19131	response	_
109-61	19132-19133	.	_

Text=These runs serve as a control for potential low-level image size effects on activation in the target area.
110-1	19134-19139	These	_
110-2	19140-19144	runs	_
110-3	19145-19150	serve	_
110-4	19151-19153	as	_
110-5	19154-19155	a	_
110-6	19156-19163	control	_
110-7	19164-19167	for	_
110-8	19168-19177	potential	_
110-9	19178-19187	low-level	_
110-10	19188-19193	image	_
110-11	19194-19198	size	_
110-12	19199-19206	effects	_
110-13	19207-19209	on	_
110-14	19210-19220	activation	_
110-15	19221-19223	in	_
110-16	19224-19227	the	_
110-17	19228-19234	target	_
110-18	19235-19239	area	_
110-19	19240-19241	.	_

Text=They will allow a comparison to be made between the same stimulus presentation with and without attempted self-regulation.
111-1	19242-19246	They	_
111-2	19247-19251	will	_
111-3	19252-19257	allow	_
111-4	19258-19259	a	_
111-5	19260-19270	comparison	_
111-6	19271-19273	to	_
111-7	19274-19276	be	_
111-8	19277-19281	made	_
111-9	19282-19289	between	_
111-10	19290-19293	the	_
111-11	19294-19298	same	_
111-12	19299-19307	stimulus	_
111-13	19308-19320	presentation	_
111-14	19321-19325	with	_
111-15	19326-19329	and	_
111-16	19330-19337	without	_
111-17	19338-19347	attempted	_
111-18	19348-19363	self-regulation	_
111-19	19364-19365	.	_

Text=Selection of both sets of pictures is based on the computer-based rating task that the participant performed during the baseline session.
112-1	19366-19375	Selection	_
112-2	19376-19378	of	_
112-3	19379-19383	both	_
112-4	19384-19388	sets	_
112-5	19389-19391	of	_
112-6	19392-19400	pictures	_
112-7	19401-19403	is	_
112-8	19404-19409	based	_
112-9	19410-19412	on	_
112-10	19413-19416	the	_
112-11	19417-19431	computer-based	_
112-12	19432-19438	rating	_
112-13	19439-19443	task	_
112-14	19444-19448	that	_
112-15	19449-19452	the	_
112-16	19453-19464	participant	_
112-17	19465-19474	performed	_
112-18	19475-19481	during	_
112-19	19482-19485	the	_
112-20	19486-19494	baseline	_
112-21	19495-19502	session	_
112-22	19503-19504	.	_

Text=Each neurofeedback run consists of seven regulation blocks of 30-s duration showing one picture exemplar whose size changes according to the participant ’ s BOLD activation in the target area.
113-1	19505-19509	Each	_
113-2	19510-19523	neurofeedback	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
113-3	19524-19527	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
113-4	19528-19536	consists	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
113-5	19537-19539	of	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
113-6	19540-19545	seven	_
113-7	19546-19556	regulation	_
113-8	19557-19563	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
113-9	19564-19566	of	_
113-10	19567-19571	30-s	_
113-11	19572-19580	duration	_
113-12	19581-19588	showing	_
113-13	19589-19592	one	_
113-14	19593-19600	picture	_
113-15	19601-19609	exemplar	_
113-16	19610-19615	whose	_
113-17	19616-19620	size	_
113-18	19621-19628	changes	_
113-19	19629-19638	according	_
113-20	19639-19641	to	_
113-21	19642-19645	the	_
113-22	19646-19657	participant	_
113-23	19658-19659	’	_
113-24	19660-19661	s	_
113-25	19662-19666	BOLD	_
113-26	19667-19677	activation	_
113-27	19678-19680	in	_
113-28	19681-19684	the	_
113-29	19685-19691	target	_
113-30	19692-19696	area	_
113-31	19697-19698	.	_

Text=Between regulation blocks, a 30-s resting block showing a fixation cross is interspersed, and each run begins with a 30-s rest block.
114-1	19699-19706	Between	_
114-2	19707-19717	regulation	_
114-3	19718-19724	blocks	_
114-4	19725-19726	,	_
114-5	19727-19728	a	_
114-6	19729-19733	30-s	_
114-7	19734-19741	resting	_
114-8	19742-19747	block	_
114-9	19748-19755	showing	_
114-10	19756-19757	a	_
114-11	19758-19766	fixation	_
114-12	19767-19772	cross	_
114-13	19773-19775	is	_
114-14	19776-19788	interspersed	_
114-15	19789-19790	,	_
114-16	19791-19794	and	_
114-17	19795-19799	each	_
114-18	19800-19803	run	_
114-19	19804-19810	begins	_
114-20	19811-19815	with	_
114-21	19816-19817	a	_
114-22	19818-19822	30-s	_
114-23	19823-19827	rest	_
114-24	19828-19833	block	_
114-25	19834-19835	.	_

Text=Feedback is provided by varying the size of the picture, which can range from between 100% of the entire projector screen (1024 × 768 pixels) and 10% of the screen, depending on the level of activation.
115-1	19836-19844	Feedback	_
115-2	19845-19847	is	_
115-3	19848-19856	provided	_
115-4	19857-19859	by	_
115-5	19860-19867	varying	_
115-6	19868-19871	the	_
115-7	19872-19876	size	_
115-8	19877-19879	of	_
115-9	19880-19883	the	_
115-10	19884-19891	picture	_
115-11	19892-19893	,	_
115-12	19894-19899	which	_
115-13	19900-19903	can	_
115-14	19904-19909	range	_
115-15	19910-19914	from	_
115-16	19915-19922	between	_
115-17	19923-19926	100	_
115-18	19927-19928	%	_
115-19	19929-19931	of	_
115-20	19932-19935	the	_
115-21	19936-19942	entire	_
115-22	19943-19952	projector	_
115-23	19953-19959	screen	_
115-24	19960-19961	(	_
115-25	19962-19966	1024	_
115-26	19967-19968	×	_
115-27	19969-19972	768	_
115-28	19973-19979	pixels	_
115-29	19980-19981	)	_
115-30	19982-19985	and	_
115-31	19986-19988	10	_
115-32	19989-19990	%	_
115-33	19991-19993	of	_
115-34	19994-19997	the	_
115-35	19998-20004	screen	_
115-36	20005-20006	,	_
115-37	20007-20016	depending	_
115-38	20017-20019	on	_
115-39	20020-20023	the	_
115-40	20024-20029	level	_
115-41	20030-20032	of	_
115-42	20033-20043	activation	_
115-43	20044-20045	.	_

Text=Down-regulation is signalled by decreasing the size of the picture, following a procedure piloted by our research group for food-related stimuli.
116-1	20046-20061	Down-regulation	_
116-2	20062-20064	is	_
116-3	20065-20074	signalled	_
116-4	20075-20077	by	_
116-5	20078-20088	decreasing	_
116-6	20089-20092	the	_
116-7	20093-20097	size	_
116-8	20098-20100	of	_
116-9	20101-20104	the	_
116-10	20105-20112	picture	_
116-11	20113-20114	,	_
116-12	20115-20124	following	_
116-13	20125-20126	a	_
116-14	20127-20136	procedure	_
116-15	20137-20144	piloted	_
116-16	20145-20147	by	_
116-17	20148-20151	our	_
116-18	20152-20160	research	_
116-19	20161-20166	group	_
116-20	20167-20170	for	_
116-21	20171-20183	food-related	_
116-22	20184-20191	stimuli	_
116-23	20192-20193	.	_

Text=Up-regulation (during exposure to other goal-related pictures) is signalled by increases in the size of the picture.
117-1	20194-20207	Up-regulation	_
117-2	20208-20209	(	_
117-3	20210-20216	during	_
117-4	20217-20225	exposure	_
117-5	20226-20228	to	_
117-6	20229-20234	other	_
117-7	20235-20247	goal-related	_
117-8	20248-20256	pictures	_
117-9	20257-20258	)	_
117-10	20259-20261	is	_
117-11	20262-20271	signalled	_
117-12	20272-20274	by	_
117-13	20275-20284	increases	_
117-14	20285-20287	in	_
117-15	20288-20291	the	_
117-16	20292-20296	size	_
117-17	20297-20299	of	_
117-18	20300-20303	the	_
117-19	20304-20311	picture	_
117-20	20312-20313	.	_

Text=The aspect ratio of the pictures is kept constant for all picture sizes.
118-1	20314-20317	The	_
118-2	20318-20324	aspect	_
118-3	20325-20330	ratio	_
118-4	20331-20333	of	_
118-5	20334-20337	the	_
118-6	20338-20346	pictures	_
118-7	20347-20349	is	_
118-8	20350-20354	kept	_
118-9	20355-20363	constant	_
118-10	20364-20367	for	_
118-11	20368-20371	all	_
118-12	20372-20379	picture	_
118-13	20380-20385	sizes	_
118-14	20386-20387	.	_

Text=The size of the picture is changed based on the percentage of the signal change in the current block compared to the baseline in the previously defined ROI.
119-1	20388-20391	The	_
119-2	20392-20396	size	_
119-3	20397-20399	of	_
119-4	20400-20403	the	_
119-5	20404-20411	picture	_
119-6	20412-20414	is	_
119-7	20415-20422	changed	_
119-8	20423-20428	based	_
119-9	20429-20431	on	_
119-10	20432-20435	the	_
119-11	20436-20446	percentage	_
119-12	20447-20449	of	_
119-13	20450-20453	the	_
119-14	20454-20460	signal	_
119-15	20461-20467	change	_
119-16	20468-20470	in	_
119-17	20471-20474	the	_
119-18	20475-20482	current	_
119-19	20483-20488	block	_
119-20	20489-20497	compared	_
119-21	20498-20500	to	_
119-22	20501-20504	the	_
119-23	20505-20513	baseline	_
119-24	20514-20516	in	_
119-25	20517-20520	the	_
119-26	20521-20531	previously	_
119-27	20532-20539	defined	_
119-28	20540-20543	ROI	_
119-29	20544-20545	.	_

Text=The last five volumes prior to the current neurofeedback block are used to calculate the baseline level.
120-1	20546-20549	The	_
120-2	20550-20554	last	_
120-3	20555-20559	five	_
120-4	20560-20567	volumes	_
120-5	20568-20573	prior	_
120-6	20574-20576	to	_
120-7	20577-20580	the	_
120-8	20581-20588	current	_
120-9	20589-20602	neurofeedback	_
120-10	20603-20608	block	_
120-11	20609-20612	are	_
120-12	20613-20617	used	_
120-13	20618-20620	to	_
120-14	20621-20630	calculate	_
120-15	20631-20634	the	_
120-16	20635-20643	baseline	_
120-17	20644-20649	level	_
120-18	20650-20651	.	_

Text=A moving average filtre of four volumes is used to overcome spikes and signal drops and to avoid large fluctuations in the size of the pictures.
121-1	20652-20653	A	_
121-2	20654-20660	moving	_
121-3	20661-20668	average	_
121-4	20669-20675	filtre	_
121-5	20676-20678	of	_
121-6	20679-20683	four	_
121-7	20684-20691	volumes	_
121-8	20692-20694	is	_
121-9	20695-20699	used	_
121-10	20700-20702	to	_
121-11	20703-20711	overcome	_
121-12	20712-20718	spikes	_
121-13	20719-20722	and	_
121-14	20723-20729	signal	_
121-15	20730-20735	drops	_
121-16	20736-20739	and	_
121-17	20740-20742	to	_
121-18	20743-20748	avoid	_
121-19	20749-20754	large	_
121-20	20755-20767	fluctuations	_
121-21	20768-20770	in	_
121-22	20771-20774	the	_
121-23	20775-20779	size	_
121-24	20780-20782	of	_
121-25	20783-20786	the	_
121-26	20787-20795	pictures	_
121-27	20796-20797	.	_

Text=The percentage signal change is calculated using this equation: The percentage signal change (PSC) is then normalised to a value between −1 and +1 by dividing the fb value by a predefined maximum PSC of 1%.
122-1	20798-20801	The	_
122-2	20802-20812	percentage	_
122-3	20813-20819	signal	_
122-4	20820-20826	change	_
122-5	20827-20829	is	_
122-6	20830-20840	calculated	_
122-7	20841-20846	using	_
122-8	20847-20851	this	_
122-9	20852-20860	equation	_
122-10	20861-20862	:	_
122-11	20863-20866	The	_
122-12	20867-20877	percentage	_
122-13	20878-20884	signal	_
122-14	20885-20891	change	_
122-15	20892-20893	(	_
122-16	20894-20897	PSC	_
122-17	20898-20899	)	_
122-18	20900-20902	is	_
122-19	20903-20907	then	_
122-20	20908-20918	normalised	_
122-21	20919-20921	to	_
122-22	20922-20923	a	_
122-23	20924-20929	value	_
122-24	20930-20937	between	_
122-25	20938-20940	−1	_
122-26	20941-20944	and	_
122-27	20945-20947	+1	_
122-28	20948-20950	by	_
122-29	20951-20959	dividing	_
122-30	20960-20963	the	_
122-31	20964-20966	fb	_
122-32	20967-20972	value	_
122-33	20973-20975	by	_
122-34	20976-20977	a	_
122-35	20978-20988	predefined	_
122-36	20989-20996	maximum	_
122-37	20997-21000	PSC	_
122-38	21001-21003	of	_
122-39	21004-21005	1	_
122-40	21006-21007	%	_
122-41	21008-21009	.	_

Text=This is done in order to be able to resize the pictures in the predefined way.
123-1	21010-21014	This	_
123-2	21015-21017	is	_
123-3	21018-21022	done	_
123-4	21023-21025	in	_
123-5	21026-21031	order	_
123-6	21032-21034	to	_
123-7	21035-21037	be	_
123-8	21038-21042	able	_
123-9	21043-21045	to	_
123-10	21046-21052	resize	_
123-11	21053-21056	the	_
123-12	21057-21065	pictures	_
123-13	21066-21068	in	_
123-14	21069-21072	the	_
123-15	21073-21083	predefined	_
123-16	21084-21087	way	_
123-17	21088-21089	.	_

Text=Between the fMRI runs, the experimenter speaks to the participant using an intercom and gives the participant the opportunity to rest.
124-1	21090-21097	Between	_
124-2	21098-21101	the	_
124-3	21102-21106	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
124-4	21107-21111	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
124-5	21112-21113	,	_
124-6	21114-21117	the	_
124-7	21118-21130	experimenter	_
124-8	21131-21137	speaks	_
124-9	21138-21140	to	_
124-10	21141-21144	the	_
124-11	21145-21156	participant	_
124-12	21157-21162	using	_
124-13	21163-21165	an	_
124-14	21166-21174	intercom	_
124-15	21175-21178	and	_
124-16	21179-21184	gives	_
124-17	21185-21188	the	_
124-18	21189-21200	participant	_
124-19	21201-21204	the	_
124-20	21205-21216	opportunity	_
124-21	21217-21219	to	_
124-22	21220-21224	rest	_
124-23	21225-21226	.	_

Text=Participants in the control group are invited to attend four behavioural assessment sessions (baseline assessment, primary assessment after 4 months, and a follow-up assessment after 8 and 12 months).
125-1	21227-21239	Participants	_
125-2	21240-21242	in	_
125-3	21243-21246	the	_
125-4	21247-21254	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-5	21255-21260	group	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-6	21261-21264	are	_
125-7	21265-21272	invited	_
125-8	21273-21275	to	_
125-9	21276-21282	attend	_
125-10	21283-21287	four	_
125-11	21288-21299	behavioural	_
125-12	21300-21310	assessment	_
125-13	21311-21319	sessions	_
125-14	21320-21321	(	_
125-15	21322-21330	baseline	_
125-16	21331-21341	assessment	_
125-17	21342-21343	,	_
125-18	21344-21351	primary	_
125-19	21352-21362	assessment	_
125-20	21363-21368	after	_
125-21	21369-21370	4	_
125-22	21371-21377	months	_
125-23	21378-21379	,	_
125-24	21380-21383	and	_
125-25	21384-21385	a	_
125-26	21386-21395	follow-up	_
125-27	21396-21406	assessment	_
125-28	21407-21412	after	_
125-29	21413-21414	8	_
125-30	21415-21418	and	_
125-31	21419-21421	12	_
125-32	21422-21428	months	_
125-33	21429-21430	)	_
125-34	21431-21432	.	_

Text=All adverse events and serious adverse events (SAEs) will be recorded on the appropriate Case Report Form.
126-1	21433-21436	All	_
126-2	21437-21444	adverse	_
126-3	21445-21451	events	_
126-4	21452-21455	and	_
126-5	21456-21463	serious	_
126-6	21464-21471	adverse	_
126-7	21472-21478	events	_
126-8	21479-21480	(	_
126-9	21481-21485	SAEs	_
126-10	21486-21487	)	_
126-11	21488-21492	will	_
126-12	21493-21495	be	_
126-13	21496-21504	recorded	_
126-14	21505-21507	on	_
126-15	21508-21511	the	_
126-16	21512-21523	appropriate	_
126-17	21524-21528	Case	_
126-18	21529-21535	Report	_
126-19	21536-21540	Form	_
126-20	21541-21542	.	_

Text=Events meeting the criteria for a SAE will be reported according to the timelines specified in the study protocol (e.g.
127-1	21543-21549	Events	_
127-2	21550-21557	meeting	_
127-3	21558-21561	the	_
127-4	21562-21570	criteria	_
127-5	21571-21574	for	_
127-6	21575-21576	a	_
127-7	21577-21580	SAE	_
127-8	21581-21585	will	_
127-9	21586-21588	be	_
127-10	21589-21597	reported	_
127-11	21598-21607	according	_
127-12	21608-21610	to	_
127-13	21611-21614	the	_
127-14	21615-21624	timelines	_
127-15	21625-21634	specified	_
127-16	21635-21637	in	_
127-17	21638-21641	the	_
127-18	21642-21647	study	_
127-19	21648-21656	protocol	_
127-20	21657-21658	(	_
127-21	21659-21662	e.g	_
127-22	21663-21664	.	_

Text=an SAE form should be completed for all SAEs within 24 h).
128-1	21665-21667	an	_
128-2	21668-21671	SAE	_
128-3	21672-21676	form	_
128-4	21677-21683	should	_
128-5	21684-21686	be	_
128-6	21687-21696	completed	_
128-7	21697-21700	for	_
128-8	21701-21704	all	_
128-9	21705-21709	SAEs	_
128-10	21710-21716	within	_
128-11	21717-21719	24	_
128-12	21720-21721	h	_
128-13	21722-21723	)	_
128-14	21724-21725	.	_

Text=Post trial, all participants will remain under the care of their primary treating physician.
129-1	21726-21730	Post	_
129-2	21731-21736	trial	_
129-3	21737-21738	,	_
129-4	21739-21742	all	_
129-5	21743-21755	participants	_
129-6	21756-21760	will	_
129-7	21761-21767	remain	_
129-8	21768-21773	under	_
129-9	21774-21777	the	_
129-10	21778-21782	care	_
129-11	21783-21785	of	_
129-12	21786-21791	their	_
129-13	21792-21799	primary	_
129-14	21800-21808	treating	_
129-15	21809-21818	physician	_
129-16	21819-21820	.	_

Text=Cardiff University will provide indemnity and compensation in the event of a claim by a participant, or by someone on a participant ’ s behalf, for negligent harm as a result of the study design and/or in respect of the protocol authors/research team.
130-1	21821-21828	Cardiff	_
130-2	21829-21839	University	_
130-3	21840-21844	will	_
130-4	21845-21852	provide	_
130-5	21853-21862	indemnity	_
130-6	21863-21866	and	_
130-7	21867-21879	compensation	_
130-8	21880-21882	in	_
130-9	21883-21886	the	_
130-10	21887-21892	event	_
130-11	21893-21895	of	_
130-12	21896-21897	a	_
130-13	21898-21903	claim	_
130-14	21904-21906	by	_
130-15	21907-21908	a	_
130-16	21909-21920	participant	_
130-17	21921-21922	,	_
130-18	21923-21925	or	_
130-19	21926-21928	by	_
130-20	21929-21936	someone	_
130-21	21937-21939	on	_
130-22	21940-21941	a	_
130-23	21942-21953	participant	_
130-24	21954-21955	’	_
130-25	21956-21957	s	_
130-26	21958-21964	behalf	_
130-27	21965-21966	,	_
130-28	21967-21970	for	_
130-29	21971-21980	negligent	_
130-30	21981-21985	harm	_
130-31	21986-21988	as	_
130-32	21989-21990	a	_
130-33	21991-21997	result	_
130-34	21998-22000	of	_
130-35	22001-22004	the	_
130-36	22005-22010	study	_
130-37	22011-22017	design	_
130-38	22018-22024	and/or	_
130-39	22025-22027	in	_
130-40	22028-22035	respect	_
130-41	22036-22038	of	_
130-42	22039-22042	the	_
130-43	22043-22051	protocol	_
130-44	22052-22068	authors/research	_
130-45	22069-22073	team	_
130-46	22074-22075	.	_

Text=Cardiff University does not provide compensation for non-negligent harm.
131-1	22076-22083	Cardiff	_
131-2	22084-22094	University	_
131-3	22095-22099	does	_
131-4	22100-22103	not	_
131-5	22104-22111	provide	_
131-6	22112-22124	compensation	_
131-7	22125-22128	for	_
131-8	22129-22142	non-negligent	_
131-9	22143-22147	harm	_
131-10	22148-22149	.	_

Text=Sample size estimation There are no published randomised trials to inform a sample size calculation for the early phase efficacy trial of the neurofeedback intervention that is being evaluated.
132-1	22150-22156	Sample	_
132-2	22157-22161	size	_
132-3	22162-22172	estimation	_
132-4	22173-22178	There	_
132-5	22179-22182	are	_
132-6	22183-22185	no	_
132-7	22186-22195	published	_
132-8	22196-22206	randomised	_
132-9	22207-22213	trials	_
132-10	22214-22216	to	_
132-11	22217-22223	inform	_
132-12	22224-22225	a	_
132-13	22226-22232	sample	_
132-14	22233-22237	size	_
132-15	22238-22249	calculation	_
132-16	22250-22253	for	_
132-17	22254-22257	the	_
132-18	22258-22263	early	_
132-19	22264-22269	phase	_
132-20	22270-22278	efficacy	_
132-21	22279-22284	trial	_
132-22	22285-22287	of	_
132-23	22288-22291	the	_
132-24	22292-22305	neurofeedback	_
132-25	22306-22318	intervention	_
132-26	22319-22323	that	_
132-27	22324-22326	is	_
132-28	22327-22332	being	_
132-29	22333-22342	evaluated	_
132-30	22343-22344	.	_

Text=However, experimental neurofeedback studies have found large effect sizes of 0.5 to 1.5, depending on the patient group that was tested.
133-1	22345-22352	However	_
133-2	22353-22354	,	_
133-3	22355-22367	experimental	_
133-4	22368-22381	neurofeedback	_
133-5	22382-22389	studies	_
133-6	22390-22394	have	_
133-7	22395-22400	found	_
133-8	22401-22406	large	_
133-9	22407-22413	effect	_
133-10	22414-22419	sizes	_
133-11	22420-22422	of	_
133-12	22423-22426	0.5	_
133-13	22427-22429	to	_
133-14	22430-22433	1.5	_
133-15	22434-22435	,	_
133-16	22436-22445	depending	_
133-17	22446-22448	on	_
133-18	22449-22452	the	_
133-19	22453-22460	patient	_
133-20	22461-22466	group	_
133-21	22467-22471	that	_
133-22	22472-22475	was	_
133-23	22476-22482	tested	_
133-24	22483-22484	.	_

Text=At a significance level of 0.05, the present sample size (from which we expect a 20% dropout rate, yielding a final size of 40 (or 20 in each group)) will allow us to detect effect sizes ranging from 0.8 with 70% power to 1.1 with 90% power.
134-1	22485-22487	At	_
134-2	22488-22489	a	_
134-3	22490-22502	significance	_
134-4	22503-22508	level	_
134-5	22509-22511	of	_
134-6	22512-22516	0.05	_
134-7	22517-22518	,	_
134-8	22519-22522	the	_
134-9	22523-22530	present	_
134-10	22531-22537	sample	_
134-11	22538-22542	size	_
134-12	22543-22544	(	_
134-13	22545-22549	from	_
134-14	22550-22555	which	_
134-15	22556-22558	we	_
134-16	22559-22565	expect	_
134-17	22566-22567	a	_
134-18	22568-22570	20	_
134-19	22571-22572	%	_
134-20	22573-22580	dropout	_
134-21	22581-22585	rate	_
134-22	22586-22587	,	_
134-23	22588-22596	yielding	_
134-24	22597-22598	a	_
134-25	22599-22604	final	_
134-26	22605-22609	size	_
134-27	22610-22612	of	_
134-28	22613-22615	40	_
134-29	22616-22617	(	_
134-30	22618-22620	or	_
134-31	22621-22623	20	_
134-32	22624-22626	in	_
134-33	22627-22631	each	_
134-34	22632-22637	group	_
134-35	22638-22639	)	_
134-36	22640-22641	)	_
134-37	22642-22646	will	_
134-38	22647-22652	allow	_
134-39	22653-22655	us	_
134-40	22656-22658	to	_
134-41	22659-22665	detect	_
134-42	22666-22672	effect	_
134-43	22673-22678	sizes	_
134-44	22679-22686	ranging	_
134-45	22687-22691	from	_
134-46	22692-22695	0.8	_
134-47	22696-22700	with	_
134-48	22701-22703	70	_
134-49	22704-22705	%	_
134-50	22706-22711	power	_
134-51	22712-22714	to	_
134-52	22715-22718	1.1	_
134-53	22719-22723	with	_
134-54	22724-22726	90	_
134-55	22727-22728	%	_
134-56	22729-22734	power	_
134-57	22735-22736	.	_

Text=This level is suitable for single-site, early-phase detection of clinically promising results.
135-1	22737-22741	This	_
135-2	22742-22747	level	_
135-3	22748-22750	is	_
135-4	22751-22759	suitable	_
135-5	22760-22763	for	_
135-6	22764-22775	single-site	_
135-7	22776-22777	,	_
135-8	22778-22789	early-phase	_
135-9	22790-22799	detection	_
135-10	22800-22802	of	_
135-11	22803-22813	clinically	_
135-12	22814-22823	promising	_
135-13	22824-22831	results	_
135-14	22832-22833	.	_

Text=Analyses One of the study investigators will perform data entry, and a second member of staff will compare the database record (the electronic Case Report Form; eCRF) with the source record (the paper Case Report Form; pCRF).
136-1	22834-22842	Analyses	_
136-2	22843-22846	One	_
136-3	22847-22849	of	_
136-4	22850-22853	the	_
136-5	22854-22859	study	_
136-6	22860-22873	investigators	_
136-7	22874-22878	will	_
136-8	22879-22886	perform	_
136-9	22887-22891	data	_
136-10	22892-22897	entry	_
136-11	22898-22899	,	_
136-12	22900-22903	and	_
136-13	22904-22905	a	_
136-14	22906-22912	second	_
136-15	22913-22919	member	_
136-16	22920-22922	of	_
136-17	22923-22928	staff	_
136-18	22929-22933	will	_
136-19	22934-22941	compare	_
136-20	22942-22945	the	_
136-21	22946-22954	database	_
136-22	22955-22961	record	_
136-23	22962-22963	(	_
136-24	22964-22967	the	_
136-25	22968-22978	electronic	_
136-26	22979-22983	Case	_
136-27	22984-22990	Report	_
136-28	22991-22995	Form	_
136-29	22996-22997	;	_
136-30	22998-23002	eCRF	_
136-31	23003-23004	)	_
136-32	23005-23009	with	_
136-33	23010-23013	the	_
136-34	23014-23020	source	_
136-35	23021-23027	record	_
136-36	23028-23029	(	_
136-37	23030-23033	the	_
136-38	23034-23039	paper	_
136-39	23040-23044	Case	_
136-40	23045-23051	Report	_
136-41	23052-23056	Form	_
136-42	23057-23058	;	_
136-43	23059-23063	pCRF	_
136-44	23064-23065	)	_
136-45	23066-23067	.	_

Text=pCRFs will be stored securely in locked filing cabinets, and the data in the eCRFs will be stored securely in the database housed at Cardiff University.
137-1	23068-23073	pCRFs	_
137-2	23074-23078	will	_
137-3	23079-23081	be	_
137-4	23082-23088	stored	_
137-5	23089-23097	securely	_
137-6	23098-23100	in	_
137-7	23101-23107	locked	_
137-8	23108-23114	filing	_
137-9	23115-23123	cabinets	_
137-10	23124-23125	,	_
137-11	23126-23129	and	_
137-12	23130-23133	the	_
137-13	23134-23138	data	_
137-14	23139-23141	in	_
137-15	23142-23145	the	_
137-16	23146-23151	eCRFs	_
137-17	23152-23156	will	_
137-18	23157-23159	be	_
137-19	23160-23166	stored	_
137-20	23167-23175	securely	_
137-21	23176-23178	in	_
137-22	23179-23182	the	_
137-23	23183-23191	database	_
137-24	23192-23198	housed	_
137-25	23199-23201	at	_
137-26	23202-23209	Cardiff	_
137-27	23210-23220	University	_
137-28	23221-23222	.	_

Text=Access to the database is restricted to named study team personnel only and in accordance with their specific roles and responsibilities.
138-1	23223-23229	Access	_
138-2	23230-23232	to	_
138-3	23233-23236	the	_
138-4	23237-23245	database	_
138-5	23246-23248	is	_
138-6	23249-23259	restricted	_
138-7	23260-23262	to	_
138-8	23263-23268	named	_
138-9	23269-23274	study	_
138-10	23275-23279	team	_
138-11	23280-23289	personnel	_
138-12	23290-23294	only	_
138-13	23295-23298	and	_
138-14	23299-23301	in	_
138-15	23302-23312	accordance	_
138-16	23313-23317	with	_
138-17	23318-23323	their	_
138-18	23324-23332	specific	_
138-19	23333-23338	roles	_
138-20	23339-23342	and	_
138-21	23343-23359	responsibilities	_
138-22	23360-23361	.	_

Text=The data management plan will contain all relevant details about how the data for the study are being handled and managed.
139-1	23362-23365	The	_
139-2	23366-23370	data	_
139-3	23371-23381	management	_
139-4	23382-23386	plan	_
139-5	23387-23391	will	_
139-6	23392-23399	contain	_
139-7	23400-23403	all	_
139-8	23404-23412	relevant	_
139-9	23413-23420	details	_
139-10	23421-23426	about	_
139-11	23427-23430	how	_
139-12	23431-23434	the	_
139-13	23435-23439	data	_
139-14	23440-23443	for	_
139-15	23444-23447	the	_
139-16	23448-23453	study	_
139-17	23454-23457	are	_
139-18	23458-23463	being	_
139-19	23464-23471	handled	_
139-20	23472-23475	and	_
139-21	23476-23483	managed	_
139-22	23484-23485	.	_

Text=The study site statistician, the principal investigator (PI), and the trial unit statistician will have access to the final dataset for study site-specific analyses and meta-analyses across the sites in BRAINTRAIN.
140-1	23486-23489	The	_
140-2	23490-23495	study	_
140-3	23496-23500	site	_
140-4	23501-23513	statistician	_
140-5	23514-23515	,	_
140-6	23516-23519	the	_
140-7	23520-23529	principal	_
140-8	23530-23542	investigator	_
140-9	23543-23544	(	_
140-10	23545-23547	PI	_
140-11	23548-23549	)	_
140-12	23550-23551	,	_
140-13	23552-23555	and	_
140-14	23556-23559	the	_
140-15	23560-23565	trial	_
140-16	23566-23570	unit	_
140-17	23571-23583	statistician	_
140-18	23584-23588	will	_
140-19	23589-23593	have	_
140-20	23594-23600	access	_
140-21	23601-23603	to	_
140-22	23604-23607	the	_
140-23	23608-23613	final	_
140-24	23614-23621	dataset	_
140-25	23622-23625	for	_
140-26	23626-23631	study	_
140-27	23632-23645	site-specific	_
140-28	23646-23654	analyses	_
140-29	23655-23658	and	_
140-30	23659-23672	meta-analyses	_
140-31	23673-23679	across	_
140-32	23680-23683	the	_
140-33	23684-23689	sites	_
140-34	23690-23692	in	_
140-35	23693-23703	BRAINTRAIN	_
140-36	23704-23705	.	_

Text=The analysis population will be on an intention-to-treat basis (as randomised) using complete data.
141-1	23706-23709	The	_
141-2	23710-23718	analysis	_
141-3	23719-23729	population	_
141-4	23730-23734	will	_
141-5	23735-23737	be	_
141-6	23738-23740	on	_
141-7	23741-23743	an	_
141-8	23744-23762	intention-to-treat	_
141-9	23763-23768	basis	_
141-10	23769-23770	(	_
141-11	23771-23773	as	_
141-12	23774-23784	randomised	_
141-13	23785-23786	)	_
141-14	23787-23792	using	_
141-15	23793-23801	complete	_
141-16	23802-23806	data	_
141-17	23807-23808	.	_

Text=We do not intend to perform imputation for missing data in this early phase study but will check for bias in any missing cohort.
142-1	23809-23811	We	_
142-2	23812-23814	do	_
142-3	23815-23818	not	_
142-4	23819-23825	intend	_
142-5	23826-23828	to	_
142-6	23829-23836	perform	_
142-7	23837-23847	imputation	_
142-8	23848-23851	for	_
142-9	23852-23859	missing	_
142-10	23860-23864	data	_
142-11	23865-23867	in	_
142-12	23868-23872	this	_
142-13	23873-23878	early	_
142-14	23879-23884	phase	_
142-15	23885-23890	study	_
142-16	23891-23894	but	_
142-17	23895-23899	will	_
142-18	23900-23905	check	_
142-19	23906-23909	for	_
142-20	23910-23914	bias	_
142-21	23915-23917	in	_
142-22	23918-23921	any	_
142-23	23922-23929	missing	_
142-24	23930-23936	cohort	_
142-25	23937-23938	.	_

Text=The anatomical and functional brain imaging data will be analysed using BrainVoyager (http: //www.brainvoyager.com) or another appropriate software package.
143-1	23939-23942	The	_
143-2	23943-23953	anatomical	_
143-3	23954-23957	and	_
143-4	23958-23968	functional	_
143-5	23969-23974	brain	_
143-6	23975-23982	imaging	_
143-7	23983-23987	data	_
143-8	23988-23992	will	_
143-9	23993-23995	be	_
143-10	23996-24004	analysed	_
143-11	24005-24010	using	_
143-12	24011-24023	BrainVoyager	_
143-13	24024-24025	(	_
143-14	24026-24030	http	_
143-15	24031-24032	:	_
143-16	24033-24055	//www.brainvoyager.com	_
143-17	24056-24057	)	_
143-18	24058-24060	or	_
143-19	24061-24068	another	_
143-20	24069-24080	appropriate	_
143-21	24081-24089	software	_
143-22	24090-24097	package	_
143-23	24098-24099	.	_

Text=A general linear model will be used to test the effects of NFT on brain activation, both in target areas and at the whole-brain level.
144-1	24100-24101	A	_
144-2	24102-24109	general	_
144-3	24110-24116	linear	_
144-4	24117-24122	model	_
144-5	24123-24127	will	_
144-6	24128-24130	be	_
144-7	24131-24135	used	_
144-8	24136-24138	to	_
144-9	24139-24143	test	_
144-10	24144-24147	the	_
144-11	24148-24155	effects	_
144-12	24156-24158	of	_
144-13	24159-24162	NFT	_
144-14	24163-24165	on	_
144-15	24166-24171	brain	_
144-16	24172-24182	activation	_
144-17	24183-24184	,	_
144-18	24185-24189	both	_
144-19	24190-24192	in	_
144-20	24193-24199	target	_
144-21	24200-24205	areas	_
144-22	24206-24209	and	_
144-23	24210-24212	at	_
144-24	24213-24216	the	_
144-25	24217-24228	whole-brain	_
144-26	24229-24234	level	_
144-27	24235-24236	.	_

Text=Specifically, we will contrast activation in neurofeedback runs with passive viewing during the perceptual control (mirror) runs.
145-1	24237-24249	Specifically	_
145-2	24250-24251	,	_
145-3	24252-24254	we	_
145-4	24255-24259	will	_
145-5	24260-24268	contrast	_
145-6	24269-24279	activation	_
145-7	24280-24282	in	_
145-8	24283-24296	neurofeedback	_
145-9	24297-24301	runs	_
145-10	24302-24306	with	_
145-11	24307-24314	passive	_
145-12	24315-24322	viewing	_
145-13	24323-24329	during	_
145-14	24330-24333	the	_
145-15	24334-24344	perceptual	_
145-16	24345-24352	control	_
145-17	24353-24354	(	_
145-18	24355-24361	mirror	_
145-19	24362-24363	)	_
145-20	24364-24368	runs	_
145-21	24369-24370	.	_

Text=We expect to find reduced activation during neurofeedback in the target and other craving-related areas, but increased activation in other areas, e.g.
146-1	24371-24373	We	_
146-2	24374-24380	expect	_
146-3	24381-24383	to	_
146-4	24384-24388	find	_
146-5	24389-24396	reduced	_
146-6	24397-24407	activation	_
146-7	24408-24414	during	_
146-8	24415-24428	neurofeedback	_
146-9	24429-24431	in	_
146-10	24432-24435	the	_
146-11	24436-24442	target	_
146-12	24443-24446	and	_
146-13	24447-24452	other	_
146-14	24453-24468	craving-related	_
146-15	24469-24474	areas	_
146-16	24475-24476	,	_
146-17	24477-24480	but	_
146-18	24481-24490	increased	_
146-19	24491-24501	activation	_
146-20	24502-24504	in	_
146-21	24505-24510	other	_
146-22	24511-24516	areas	_
146-23	24517-24518	,	_
146-24	24519-24522	e.g	_
146-25	24523-24524	.	_

Text=those related to emotional control or which represent alternative, socially desirable goals (in the runs that include the goal-related pictures).
147-1	24525-24530	those	_
147-2	24531-24538	related	_
147-3	24539-24541	to	_
147-4	24542-24551	emotional	_
147-5	24552-24559	control	_
147-6	24560-24562	or	_
147-7	24563-24568	which	_
147-8	24569-24578	represent	_
147-9	24579-24590	alternative	_
147-10	24591-24592	,	_
147-11	24593-24601	socially	_
147-12	24602-24611	desirable	_
147-13	24612-24617	goals	_
147-14	24618-24619	(	_
147-15	24620-24622	in	_
147-16	24623-24626	the	_
147-17	24627-24631	runs	_
147-18	24632-24636	that	_
147-19	24637-24644	include	_
147-20	24645-24648	the	_
147-21	24649-24661	goal-related	_
147-22	24662-24670	pictures	_
147-23	24671-24672	)	_
147-24	24673-24674	.	_

Text=Participants ’ improvement in self-regulation across the sessions will be analysed using brain-activation parameters in repeated the correct term is definitely measures (with an "s") NOT measure.
148-1	24675-24687	Participants	_
148-2	24688-24689	’	_
148-3	24690-24701	improvement	_
148-4	24702-24704	in	_
148-5	24705-24720	self-regulation	_
148-6	24721-24727	across	_
148-7	24728-24731	the	_
148-8	24732-24740	sessions	_
148-9	24741-24745	will	_
148-10	24746-24748	be	_
148-11	24749-24757	analysed	_
148-12	24758-24763	using	_
148-13	24764-24780	brain-activation	_
148-14	24781-24791	parameters	_
148-15	24792-24794	in	_
148-16	24795-24803	repeated	_
148-17	24804-24807	the	_
148-18	24808-24815	correct	_
148-19	24816-24820	term	_
148-20	24821-24823	is	_
148-21	24824-24834	definitely	_
148-22	24835-24843	measures	_
148-23	24844-24845	(	_
148-24	24846-24850	with	_
148-25	24851-24853	an	_
148-26	24854-24856	``	_
148-27	24857-24858	s	_
148-28	24859-24861	''	_
148-29	24862-24863	)	_
148-30	24864-24867	NOT	_
148-31	24868-24875	measure	_
148-32	24876-24877	.	_

Text=Analyses of variance (ANOVAS).
149-1	24878-24886	Analyses	_
149-2	24887-24889	of	_
149-3	24890-24898	variance	_
149-4	24899-24900	(	_
149-5	24901-24907	ANOVAS	_
149-6	24908-24909	)	_
149-7	24910-24911	.	_

Text=The ability to self-regulate will also be correlated with online and offline craving scores obtained during each session.
150-1	24912-24915	The	_
150-2	24916-24923	ability	_
150-3	24924-24926	to	_
150-4	24927-24940	self-regulate	_
150-5	24941-24945	will	_
150-6	24946-24950	also	_
150-7	24951-24953	be	_
150-8	24954-24964	correlated	_
150-9	24965-24969	with	_
150-10	24970-24976	online	_
150-11	24977-24980	and	_
150-12	24981-24988	offline	_
150-13	24989-24996	craving	_
150-14	24997-25003	scores	_
150-15	25004-25012	obtained	_
150-16	25013-25019	during	_
150-17	25020-25024	each	_
150-18	25025-25032	session	_
150-19	25033-25034	.	_

Text=The behavioural data will be analysed using SPSS or another appropriate statistical software package.
151-1	25035-25038	The	_
151-2	25039-25050	behavioural	_
151-3	25051-25055	data	_
151-4	25056-25060	will	_
151-5	25061-25063	be	_
151-6	25064-25072	analysed	_
151-7	25073-25078	using	_
151-8	25079-25083	SPSS	_
151-9	25084-25086	or	_
151-10	25087-25094	another	_
151-11	25095-25106	appropriate	_
151-12	25107-25118	statistical	_
151-13	25119-25127	software	_
151-14	25128-25135	package	_
151-15	25136-25137	.	_

Text=The primary analyses will compare the experimental and control groups on three drinking indices (percentage of days abstinent, drinks per drinking day, and percentage of days of heavy drinking) at the primary endpoint (4 months after the baseline assessment).
152-1	25138-25141	The	_
152-2	25142-25149	primary	_
152-3	25150-25158	analyses	_
152-4	25159-25163	will	_
152-5	25164-25171	compare	_
152-6	25172-25175	the	_
152-7	25176-25188	experimental	_
152-8	25189-25192	and	_
152-9	25193-25200	control	_
152-10	25201-25207	groups	_
152-11	25208-25210	on	_
152-12	25211-25216	three	_
152-13	25217-25225	drinking	_
152-14	25226-25233	indices	_
152-15	25234-25235	(	_
152-16	25236-25246	percentage	_
152-17	25247-25249	of	_
152-18	25250-25254	days	_
152-19	25255-25264	abstinent	_
152-20	25265-25266	,	_
152-21	25267-25273	drinks	_
152-22	25274-25277	per	_
152-23	25278-25286	drinking	_
152-24	25287-25290	day	_
152-25	25291-25292	,	_
152-26	25293-25296	and	_
152-27	25297-25307	percentage	_
152-28	25308-25310	of	_
152-29	25311-25315	days	_
152-30	25316-25318	of	_
152-31	25319-25324	heavy	_
152-32	25325-25333	drinking	_
152-33	25334-25335	)	_
152-34	25336-25338	at	_
152-35	25339-25342	the	_
152-36	25343-25350	primary	_
152-37	25351-25359	endpoint	_
152-38	25360-25361	(	_
152-39	25362-25363	4	_
152-40	25364-25370	months	_
152-41	25371-25376	after	_
152-42	25377-25380	the	_
152-43	25381-25389	baseline	_
152-44	25390-25400	assessment	_
152-45	25401-25402	)	_
152-46	25403-25404	.	_

Text=For these analyses, a general linear model will be used.
153-1	25405-25408	For	_
153-2	25409-25414	these	_
153-3	25415-25423	analyses	_
153-4	25424-25425	,	_
153-5	25426-25427	a	_
153-6	25428-25435	general	_
153-7	25436-25442	linear	_
153-8	25443-25448	model	_
153-9	25449-25453	will	_
153-10	25454-25456	be	_
153-11	25457-25461	used	_
153-12	25462-25463	.	_

Text=Covariates will include potential variables that determine participants ’ success with the NFT (e.g.
154-1	25464-25474	Covariates	_
154-2	25475-25479	will	_
154-3	25480-25487	include	_
154-4	25488-25497	potential	_
154-5	25498-25507	variables	_
154-6	25508-25512	that	_
154-7	25513-25522	determine	_
154-8	25523-25535	participants	_
154-9	25536-25537	’	_
154-10	25538-25545	success	_
154-11	25546-25550	with	_
154-12	25551-25554	the	_
154-13	25555-25558	NFT	_
154-14	25559-25560	(	_
154-15	25561-25564	e.g	_
154-16	25565-25566	.	_

Text=their age and gender and drinking indices at baseline) and the variables that were used to balance the two groups during randomisation.
155-1	25567-25572	their	_
155-2	25573-25576	age	_
155-3	25577-25580	and	_
155-4	25581-25587	gender	_
155-5	25588-25591	and	_
155-6	25592-25600	drinking	_
155-7	25601-25608	indices	_
155-8	25609-25611	at	_
155-9	25612-25620	baseline	_
155-10	25621-25622	)	_
155-11	25623-25626	and	_
155-12	25627-25630	the	_
155-13	25631-25640	variables	_
155-14	25641-25645	that	_
155-15	25646-25650	were	_
155-16	25651-25655	used	_
155-17	25656-25658	to	_
155-18	25659-25666	balance	_
155-19	25667-25670	the	_
155-20	25671-25674	two	_
155-21	25675-25681	groups	_
155-22	25682-25688	during	_
155-23	25689-25702	randomisation	_
155-24	25703-25704	.	_

Text=Effect sizes for the intervention will be evaluated using confidence intervals around the group difference.
156-1	25705-25711	Effect	_
156-2	25712-25717	sizes	_
156-3	25718-25721	for	_
156-4	25722-25725	the	_
156-5	25726-25738	intervention	_
156-6	25739-25743	will	_
156-7	25744-25746	be	_
156-8	25747-25756	evaluated	_
156-9	25757-25762	using	_
156-10	25763-25773	confidence	_
156-11	25774-25783	intervals	_
156-12	25784-25790	around	_
156-13	25791-25794	the	_
156-14	25795-25800	group	_
156-15	25801-25811	difference	_
156-16	25812-25813	.	_

Text=Analyses will be conducted separately for the follow-up assessments, again using general linear models adjusted for baseline covariates and randomisation variables.
157-1	25814-25822	Analyses	_
157-2	25823-25827	will	_
157-3	25828-25830	be	_
157-4	25831-25840	conducted	_
157-5	25841-25851	separately	_
157-6	25852-25855	for	_
157-7	25856-25859	the	_
157-8	25860-25869	follow-up	_
157-9	25870-25881	assessments	_
157-10	25882-25883	,	_
157-11	25884-25889	again	_
157-12	25890-25895	using	_
157-13	25896-25903	general	_
157-14	25904-25910	linear	_
157-15	25911-25917	models	_
157-16	25918-25926	adjusted	_
157-17	25927-25930	for	_
157-18	25931-25939	baseline	_
157-19	25940-25950	covariates	_
157-20	25951-25954	and	_
157-21	25955-25968	randomisation	_
157-22	25969-25978	variables	_
157-23	25979-25980	.	_

Text=Outcome measures related to craving will be evaluated for both immediate and sustained effects of the NFT.
158-1	25981-25988	Outcome	_
158-2	25989-25997	measures	_
158-3	25998-26005	related	_
158-4	26006-26008	to	_
158-5	26009-26016	craving	_
158-6	26017-26021	will	_
158-7	26022-26024	be	_
158-8	26025-26034	evaluated	_
158-9	26035-26038	for	_
158-10	26039-26043	both	_
158-11	26044-26053	immediate	_
158-12	26054-26057	and	_
158-13	26058-26067	sustained	_
158-14	26068-26075	effects	_
158-15	26076-26078	of	_
158-16	26079-26082	the	_
158-17	26083-26086	NFT	_
158-18	26087-26088	.	_

Text=In exploratory analyses, data from the homework diaries will be examined for a potential relationship between the amount of self-regulation practice that participants report and their scores on craving and alcohol consumption.
159-1	26089-26091	In	_
159-2	26092-26103	exploratory	_
159-3	26104-26112	analyses	_
159-4	26113-26114	,	_
159-5	26115-26119	data	_
159-6	26120-26124	from	_
159-7	26125-26128	the	_
159-8	26129-26137	homework	_
159-9	26138-26145	diaries	_
159-10	26146-26150	will	_
159-11	26151-26153	be	_
159-12	26154-26162	examined	_
159-13	26163-26166	for	_
159-14	26167-26168	a	_
159-15	26169-26178	potential	_
159-16	26179-26191	relationship	_
159-17	26192-26199	between	_
159-18	26200-26203	the	_
159-19	26204-26210	amount	_
159-20	26211-26213	of	_
159-21	26214-26229	self-regulation	_
159-22	26230-26238	practice	_
159-23	26239-26243	that	_
159-24	26244-26256	participants	_
159-25	26257-26263	report	_
159-26	26264-26267	and	_
159-27	26268-26273	their	_
159-28	26274-26280	scores	_
159-29	26281-26283	on	_
159-30	26284-26291	craving	_
159-31	26292-26295	and	_
159-32	26296-26303	alcohol	_
159-33	26304-26315	consumption	_
159-34	26316-26317	.	_

Text=Finally, the relationship between nonalcohol-related measures (e.g.
160-1	26318-26325	Finally	_
160-2	26326-26327	,	_
160-3	26328-26331	the	_
160-4	26332-26344	relationship	_
160-5	26345-26352	between	_
160-6	26353-26371	nonalcohol-related	_
160-7	26372-26380	measures	_
160-8	26381-26382	(	_
160-9	26383-26386	e.g	_
160-10	26387-26388	.	_

Text=thought control ability, intellectual ability) and the alcohol-related outcome measures will be examined using analysis of covariance (ANCOVA) or correlational and regression analyses.
161-1	26389-26396	thought	_
161-2	26397-26404	control	_
161-3	26405-26412	ability	_
161-4	26413-26414	,	_
161-5	26415-26427	intellectual	_
161-6	26428-26435	ability	_
161-7	26436-26437	)	_
161-8	26438-26441	and	_
161-9	26442-26445	the	_
161-10	26446-26461	alcohol-related	_
161-11	26462-26469	outcome	_
161-12	26470-26478	measures	_
161-13	26479-26483	will	_
161-14	26484-26486	be	_
161-15	26487-26495	examined	_
161-16	26496-26501	using	_
161-17	26502-26510	analysis	_
161-18	26511-26513	of	_
161-19	26514-26524	covariance	_
161-20	26525-26526	(	_
161-21	26527-26533	ANCOVA	_
161-22	26534-26535	)	_
161-23	26536-26538	or	_
161-24	26539-26552	correlational	_
161-25	26553-26556	and	_
161-26	26557-26567	regression	_
161-27	26568-26576	analyses	_
161-28	26577-26578	.	_

Text=Nonspecific effects of the NFT on participants ’ mood will be examined using the measures related to emotional processes (e.g.
162-1	26579-26590	Nonspecific	_
162-2	26591-26598	effects	_
162-3	26599-26601	of	_
162-4	26602-26605	the	_
162-5	26606-26609	NFT	_
162-6	26610-26612	on	_
162-7	26613-26625	participants	_
162-8	26626-26627	’	_
162-9	26628-26632	mood	_
162-10	26633-26637	will	_
162-11	26638-26640	be	_
162-12	26641-26649	examined	_
162-13	26650-26655	using	_
162-14	26656-26659	the	_
162-15	26660-26668	measures	_
162-16	26669-26676	related	_
162-17	26677-26679	to	_
162-18	26680-26689	emotional	_
162-19	26690-26699	processes	_
162-20	26700-26701	(	_
162-21	26702-26705	e.g	_
162-22	26706-26707	.	_

Text=the POMS).
163-1	26708-26711	the	_
163-2	26712-26716	POMS	_
163-3	26717-26718	)	_
163-4	26719-26720	.	_

Text=A publication policy will be developed and reviewed during the course of the trial, which will include details of dissemination plans to health care professionals.
164-1	26721-26722	A	_
164-2	26723-26734	publication	_
164-3	26735-26741	policy	_
164-4	26742-26746	will	_
164-5	26747-26749	be	_
164-6	26750-26759	developed	_
164-7	26760-26763	and	_
164-8	26764-26772	reviewed	_
164-9	26773-26779	during	_
164-10	26780-26783	the	_
164-11	26784-26790	course	_
164-12	26791-26793	of	_
164-13	26794-26797	the	_
164-14	26798-26803	trial	_
164-15	26804-26805	,	_
164-16	26806-26811	which	_
164-17	26812-26816	will	_
164-18	26817-26824	include	_
164-19	26825-26832	details	_
164-20	26833-26835	of	_
164-21	26836-26849	dissemination	_
164-22	26850-26855	plans	_
164-23	26856-26858	to	_
164-24	26859-26865	health	_
164-25	26866-26870	care	_
164-26	26871-26884	professionals	_
164-27	26885-26886	.	_

Text=Publications from the BRAINTRAIN consortium will be coordinated by the Executive Committee of BRAINTRAIN (chaired by the PI) in collaboration with the funding organisation.
165-1	26887-26899	Publications	_
165-2	26900-26904	from	_
165-3	26905-26908	the	_
165-4	26909-26919	BRAINTRAIN	_
165-5	26920-26930	consortium	_
165-6	26931-26935	will	_
165-7	26936-26938	be	_
165-8	26939-26950	coordinated	_
165-9	26951-26953	by	_
165-10	26954-26957	the	_
165-11	26958-26967	Executive	_
165-12	26968-26977	Committee	_
165-13	26978-26980	of	_
165-14	26981-26991	BRAINTRAIN	_
165-15	26992-26993	(	_
165-16	26994-27001	chaired	_
165-17	27002-27004	by	_
165-18	27005-27008	the	_
165-19	27009-27011	PI	_
165-20	27012-27013	)	_
165-21	27014-27016	in	_
165-22	27017-27030	collaboration	_
165-23	27031-27035	with	_
165-24	27036-27039	the	_
165-25	27040-27047	funding	_
165-26	27048-27060	organisation	_
165-27	27061-27062	.	_

Text=The trial results will be submitted for publication in an online open access journal.
166-1	27063-27066	The	_
166-2	27067-27072	trial	_
166-3	27073-27080	results	_
166-4	27081-27085	will	_
166-5	27086-27088	be	_
166-6	27089-27098	submitted	_
166-7	27099-27102	for	_
166-8	27103-27114	publication	_
166-9	27115-27117	in	_
166-10	27118-27120	an	_
166-11	27121-27127	online	_
166-12	27128-27132	open	_
166-13	27133-27139	access	_
166-14	27140-27147	journal	_
166-15	27148-27149	.	_

